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The thin layer of crude mucus lining the human gastric mucosa protects the delicate 
gastric epithelium from the high shear forces associated with digestion. Gastric mucus 
is composed largely of water (>90%)  and a complex mixture of organic components 
such as enzymes, various serum and cellular macromolecules, sloughed cells, 
bactericidal proteins, plasma proteins, inorganic ions and very importantly the 
mucins, that impart to it its gel-forming properties. Mucins are large heterogenous 
polymers that are difficult to characterize by traditional biochemical methods. 
However mucins from different regions of the body do share common features such 
as a low protein content of approximately 20% by weight and a carbohydrate content 
of 70 to 80% by weight. Mucins are characterized by a variable number of tandem 
repeat regions rich in serine, threonine and proline with the serine and threonine being 
potential sites for O-glycosylation. In contrast to the glycosylated region is the 
‘naked’ region rich in cysteine and susceptible to proteolysis. The cysteine residues 
enable mucin monomers to form polymers by disulphide bridges. 
 
Alterations of mucin expression take place in gastric carcinomas. Our laboratory 
previously reported the presence of a 40-50 kDa glycoprotein in the mucus of patients 
with gastric cancer that associated with albumin. The primary aims of our study were 
to develop an antibody to this 40-50 kDa glycoprotein, and to determine the location 
of its expression in gastric tissue by the immunohistochemical method, ranging from 
normal, to premalignant to cancer. The final aim was to identify this unknown 
glycoprotein by proteomic analysis. The reactivity of the antibody to the mucin and its 
40-50 kDa component was determined by Western Blotting. 
 
We collected gastric mucus scrapings by gentle scraping of the mucosa with a sterile 
glass slide from 27 gastrectomy specimens resected for carcinoma of the stomach. 
Mucus samples from each patient were collected within 20 min after surgical 
resection, on ice. Mucins were extracted from the crude mucus gel scrapings in 6 M 
guanidinium chloride in a cocktail of proteinase inhibitors and purified by density 
gradient ultra-centrifugation in CsCl/4 M guanidinium chloride, for 48 h at 105 000 x 











sodium dodecyl sulphate polyacrylamide-gel electrophoresis (SDS-PAGE). The 40-50 
kDa glycoprotein was separated from the mucins by SDS-PAGE, stained with 
periodic acid Schiff (PAS) base. Its association with albumin was confirmed by 
staining with Coomassie Brilliant Blue.  A Ponceau S stain of this gel indicated the 
position of albumin, allowing the gel to be sliced in exactly the position of the 40-50 
kDa glycoprotein, which was then prepared for immunization of a rabbit. The 
antibody developed was then tested for homogeneity and cross reactivity by dot blot 
and western blotting methods, and further used to determine the localization of this 
40-50 kDa glycoprotein in human gastric tissue. 
 
In the normal gastric mucosa, the 40-50 kDa glycoprotein was expressed in parietal 
cells and not in the mucus producing cells. In intestinal metaplasia (IM), a 
premaligant condition, the 40-50 kDa glycoprotein was expressed in the columnar 
cells. The 40-50 kDa glycoprotein was expressed in the intestinal, diffuse, mucinous, 
signet-ring cell and mucinous type gastric carcinomas. The intestinal type carcinoma 
was the predominant carcinoma in this study and it is considered to be an “epidemic 
type” of cancer in high-risk populations in the Western Cape region of South Africa. 
The pre-cancerous stage (IM) of the intestinal type carcinoma represents a prolonged 
and complex process, part of which results in the transformation of the normal 
mucosa into an intestinal type of mucosa. The diffuse type carcinoma, which is 
relatively more frequent in low-risk populations and is not preceded by well-defined 
precancerous lesions, was less observed in our study.  
 
Using proteomics, we performed a more complete analysis of the 40-50 kDa 
glycoprotein. We performed two-dimensional polyacrylamide gel electrophoresis (2-
D PAGE) in combination with MALDI-TOF MS to define the protein components of 
the 40-50 kDa glycoprotein and to identify it. Purified mucin from gastric cancer 
specimens were separated by 2-D PAGE which allowed high resolution and 
reproducibility. Precision protein standards were used as molecular weight markers. 
Gels were stained with Coomassie Brilliant Blue and PAS. The 40-50 kDa 
glycoprotein separated as four spots (three on Coommassie Blue and one on PAS) on 
2-D PAGE running side-by-side on the protein gel at Mr 40 to 50 kDa.  The spots 
were excised from the gels and digested with trypsin. Fragments where measured by 











TOF MS), to permit successful protein identification. The peptide mass fingerprint 
generated from the 4 spots was then used to search the NCBI database to identify the 
proteins. Three of the four proteins (from the Coommassie Blue stained gel) were 
identified as alpha-1-acid glycoprotein (AGP) also known as orosomucoid. We were 
unable to positively identify the fourth PAS positive spot on the PAS gel and this 
could possibly be due to interference in the MALDI analysis caused by the PAS stain 
or the extensive glycosylation of the protein. The identification of the 40-50 kDa 
glycoprotein as alpha-1-acid glycoprotein (AGP) confirmed previous findings based 
on an amino acid analysis of this glycoprotein being an N-linked one and not an O-
linked glycoprotein, like mucin.  
 
AGP or orosomucoid is an acute-phase protein with a high carbohydrate content 
(more than 40%) which could explain its fractionation with mucins in a CsCl density 
gradient. A number of activities of possible physiological significance have been 
ascribed to this protein, such as its immunomodulatory effects and activities related to 
the immune function of different blood cell types. AGP is produced mainly in the 
liver by hepatic cells, but extra-hepatic expression has been reported in several other 
tissues including human and bovine epithelial cells, stimulated alveolar macrophages, 
human endothelial cells and the prostate gland.  
 
In cancer, AGP has been shown (in vivo) to have no effect on the basal activity of 
natural killer cells (NK), but inhibited the increase of NK cytotoxicicity induced by 
IFNy and IFNα. In colon cancer, evidence has been presented that AGP enhances the 
invasiveness and metastatic potential of malignant cells. It remains unclear what part 
AGP plays in the pathophysiology of stomach cancer. In light of what has been 
reported on AGP, the consistent and high expression of this glycoprotein (reported by 
us) at the tumour site then provides the rationale to exploit its presence in pre-
malignant and malignant conditions to produce a clinically useful marker for gastric 
cancer, with potential use as a screening tool in areas such as the Western Cape region 
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Mammalian epithelial surfaces of the gastrointestinal, respiratory, and reproductive 
tracts are coated by a thin layer of mucus approximately 90 µm and 300 µm on the 
surface of gastric mucosa of the rat and humans respectively (Kerss et al., 1982; Allen 
et al., 1989). Mucus is a complex and viscous secretion synthesized by specialized 
mucous cells in the columnar epithelium that lines and adheres to all of the organs 
that are exposed to the external environment. The composition, properties, and 
functions of this dynamic secretion differ between epithelial tissues. Mucus serves 
many functions, among them lubrication for the passage of food and faecal material, 
maintenance of a hydrated layer over the epithelium, a barrier against pathogens, 
noxious substances and destructive hydrolases and as a permeable gel layer for the 
exchange of gases and nutrients with the underlying epithelium (Allen, 1981; Neutra, 
1987; Forstner and Forstner, 1994).  
 
Mucus is the first barrier with which nutrients and enteric drugs must interact and 
diffuse through, in order to be absorbed and gain access to the circulatory system and 
their target end-organs. Mucus itself can also act as a target with its binding sites for 
bacterial adhesions. Both non-specific and specific mucoadhesive formulations may 
be targeted to the mucus and this is likely to prevent targeting devices aimed at 
epithelial cellular ligands from reaching their goal. In addition to its protective 
functions, mucus is also involved in many disease processes. Regulation of mucus 
secretion has been coupled to a variety of factors such as pro-inflammatory cytokines 
(interleukin-4, interleukin-13, epidermal growth factor, and tumor necrosis factor-
alpha), ATP, bacterial exoproducts, and host proteases (Forstner, 1995; Plaisancie et 
al., 1998; Nadel and Burgel, 2001; Levine et al., 1995).   
 
In the cervical tract, the biological function of mucus varies with its physical 











period is penetrated much more easily by the spermatozoa than is the tenacious mucus 
plug of the luteal phase (Chantler, 1982).  
 
Mucus in the tear film on the surface of the eye is secreted by conjunctival goblet 
cells and provides a protective covering that prevents pathogen penetration and 
desiccation of the underlying epithelium (Gipson, 2004).  
 
The airway mucus gel entraps foreign particles and pathogens and also dissolves 
noxious gases, facilitating their clearance from the lung by means of ciliary transport 
or coughing (Knowles and Boucher, 2002). This highly hydrated gel, in conjunction 
with ciliated epithelial cells, is essential for the maintenance of sterile and 
unobstructed airways.  
 
The high rate of mucus accumulation in the colon provides good lubrication, crucial 
to its function, and is also important in providing a suitable environment for the 
endogenous microflora (Allen and Pearson, 1993). 
 
Mucus is composed primarily of water, but also contains salts, lipids such as fatty 
acids, glycoproteins, phospholipids and cholesterol (Allen, 1981) and proteins which 
have a defensive purpose such as lysozyme, immunoglobulins, defensins, growth 
factors and trefoil factors (Flemstrom et al., 1999; Corfield et al., 2000; Roberton et 
al,. 2005; Kouznetsova et al., 2004). 
 
Although most of mucus is water, high molecular weight glycoproteins known as 
mucins are the major component of mucus, giving it its protective, hydrophilic and 
rheological properties (Verdugo et al., 1983). Mucins, characterized by their high 
density of O-linked oligosaccharide substitution, are responsible for the biological 
properties of a continuous, insoluble and adherent mucus gel that protects the gastric 
mucosa from the hostile environment in the lumen (Allen, 1981). 
 
1.2  Gastrointestinal mucus 
 
The stomach is normally protected by a layer of mucus, reportedly ranging in depth to 











consists of two separable, physically distinct mucus gel layers termed shear resistant 
and shear-compliant (Figure 1.1). In the mammalian gastric mucosa, there are mainly 
two types of mucus-secreting cells, namely the surface mucous cells and the glandular 
mucous cells. The adherent gastric mucus gel (shear resistant), maintained by multiple 
interaction types (Taylor et al., 2003), is distinctly a stronger secretion and provides a 
stable unstirred layer and maintains a pH gradient from acid in the lumen 
(approximately pH 2) to near neutral pH (approximately pH 7) at the mucosal surface 
(Schade et al., 1994). This layer is considered to protect the mucosa from acid, pepsin 
and other damaging agents. The relative thickness of the two component layers of the 
mucus gel varies for different regions of the gut (Atuna et al., 2001) (Figure 1.1). 
 
The gastric mucosa produces two rheologically distinct gastric mucus secretions 
(Taylor et al., 2004) composed of structurally distinct mucin populations with respect 
to the potential structure to function relationships (Fogg et al., 1996) within the total 
mucus secretion. Atuna et al. (2001) observed the presence of two mucus layers (in 
vivo) in the rat gastrointestinal mucosa (Figure 1.1). The shear-resistant mucus gel has 
ideal rheological properties to form a firm protective barrier resistant to shear and 
maintaining the stable surface unstirred layer, essential for the mucus bicarbonate 
barrier. Pepsin, in vivo and in vitro has been shown to digest only the surface of the 
adherent mucus gel, being unable to penetrate the gel matrix (Allen et al., 1993; Bell 
et al., 1985). Thus the concentration of mucus glycoprotein (mucin) in the mucus may 
be the most important parameter which determines the special rheological features of 
mucus required in a special functional context. 
 
Another clearly identifiable function of gastric mucus is that of a lubricant attenuating 
the shear stress on the mucosa that results from the mechanical forces associated with 
digestion (Allen, 1989). In stomachs full of food, the shear-compliant mucus is almost 
absent from the mucosal surface and is found forming strands of mucus visible on the 
food bolus (Taylor et al., 2004). During digestion, the shear-compliant secretion, 
which changes into a viscous liquid when subjected to even low mechanical shear 
stress, acts as the ideal lubricant, facilitating the movement of solid matter through the 
gut during the digestive processes. Throughout the gut, the viscous mucus secretion 
acts as a lubricant facilitating the passage of digestive matter and protecting the 













Figure 1.1 A schematic diagram showing the two mucus gel layers in the gastrointestinal tract in 
the corpus, antrum, duodenum, jejunum, ileum, and colon adherent to the surface of the 
epithelium providing an interface between the lumen and the mucosa. In the stomach a continuous 
layer of mucus forms a barrier between the erosive gastric contents and the underlyimg mucosa. The 
mucus layer in the antrum is thicker (due to the adherent mucus layer) compared with the corpus. The 
small intestine has a very thin discontinuous mucus gel layer. In the colon and ileum, the mucus layer 
is very thick (up to 4-fold thicker) compared with that in other regions of the gut. Most of the 
difference in mucus thickness is due to the loosely adherent mucus which is continuously renewed after 
removal while the firmly adherent mucus layer remains intact (reproduced from Atuna et al., 2001). 
 
 
1.3 Mucus renewal 
 
Mucus is known to be continually produced from the epithelial surface in the gut, and 
lost to the lumen during renewal (Sababi et al., 1995; Plaisancie et al., 1998). This 
turnover displaces microparticles specifically bound to the mucus surface. The loosely 
adherent mucus, which is rapidly replaced after its removal, has more lubricative 
properties in vivo while the firmly adherent gel, which forms a thick layer over the 
gastric and colonic mucosal surfaces, acts as a relatively stable protective barrier. In 
the colon the mucus layer provides an essential environment for the enteric 











mechanical sloughing (from a motile gut, passage of faeces, etc.) is normally balanced 
by secretion of new mucus to maintain the thickness of the adherent gel layer seen in 
vivo (Allen et al., 1998) (Figure 1.2), thus maintaining a dynamic balance between 





Figure 1.2 A diagrammatic representation of mucus renewal in vivo.  The thickness of the adherent 
gastrointestinal mucus layer is a balance between its secretion rate and its erosion through enzymatic 
digestion by luminal proteases and mechanical shear. Normally, mucus secretion is sufficient to 
maintain a continuous barrier across the colonic epithelium. The removal of the loosely adherent mucus 
layer by mechanical shear forces and erosion by the mucolytic proteinases stimulates the accumulation 
of new mucus in the colon (reproduced from Allen et al., 1998).  
 
1.4 Definition of mucin 
 
Mucins, the major and important components of all mucus secreted from epithelial 
cells covering the surface of epithelial tissues (Kim et al., 1996), are complex O-
linked glycoproteins characterized by the presence of at least one large region of the 
polypeptide rich in serine and threonine residues, termed the mucin domain. These 
hydroxylated amino acids are the sites of covalent attachment, via the linkage sugar 
N-acetylgalactosamine (GalNAc), of a diverse array of O-glycans, many of which are 
sialylated or sulfated. As a consequence mucins are polyanionic, and a high 
percentage (typically more than 70%) of their mass is carbohydrate arranged in a 











1.5 Mucin biosynthesis 
 
Making a mucin is a complex multistep process which starts after the MUC protein 
backbone (apomucin) is encoded by a MUC gene. In the endoplasmic reticulum the 
apomucin undergoes N-glycosylation and intramolecular disulfide bond formation 
(McCool et al., 1994; Asker et al., 1998; Dekker and Strous, 1990) (Figure 1.3). The 
apomucin is further maintained in an open conformation to expose the sugar acceptor 
sites to the Golgi enzymes (glycosyltransferases) which will then attach and elaborate 
the vast numbers of O-glycan chains (Hang and Bertozzi, 2005).  
 
In the Golgi, GalNAc is the first glycan to be added to serine and threonine residues. 
This key step is catalyzed by polypeptide-GalNAc transferases (ppGal-NAcTs) and is 
important for the presentation of acceptor sites for other ppGalNAcTs and subsequent 
glycosyltransferases responsible for the elaboration of the O-glycan core. The 
addition of GalNAc to the apomucin is suggested to be completed prior to further 
elaboration of the glycan chains (Sheehan et al., 2004). 
 
Glycosylation patterns are known to be tissue dependent and it is therefore likely that 
the structure of the carbohydrate chains will differ according to the tissue in which the 
mucin is expressed.  
 
After glycosylation, the dimers are further polymerized to form mucins (Thornton et 
al., 1990; Sheehan et al., 1999, 2000) which then transit the trans- Golgi network 
(Perez-Vilar and Hill, 1999) where they may be packaged, in a highly condensed 
manner, into secretory granules (Perez-Vilar et al., 2005) (Figure 1.3). The major 
steps in the synthesis of a polymeric mucin (steps 1–5) and the location of these 
events within the mucin-secreting cell are summarised (Thornton et al., 2008) below 












































Figure 1.3 Diagrammatic representation of polymeric mucin biosynthesis. (1) In the ER, the 
translated mucin polypeptide undergoes N-glycosylation and (2) intramolecular disulfide bond 
formation. (3) In the cis Golgi, GalNAc is added to serine and threonine residues in the mucin domains. 
(4) These glycan chains are further elaborated as the mucin transits through the Golgi. (5) In the trans-
Golgi network, or in the secretory granule, the mucin dimers polymerize and give rise to one linear 












1.6 Mucin protein backbone (apomucin) 
 
Mucins are classified by their MUC protein backbone, which is encoded by a MUC 
gene. The mucin protein backbone, making up 20% of the molecular mass, is made up 
of two regions. First, a central glycosylated region (mucin domain), which is 
comprised of a large number of tandem repeats (TRs) that are rich in serine, threonine 
and proline (STP repeats), which can make up greater than 60% of the amino acids. 
The number of TRs in a MUC protein determine mucin size as they elongate the 
protein backbone and thus increase mucin molecular mass. Serine (Ser) and threonine 
(Thr) are the sites for the attachment to the linkage sugar N-acetylgalactosamine 
(Verma and Davidson, 1994). The second region, located at the amino (N) and 
carboxy (C) terminals, and sometimes interspersed between the STP-repeats, are 
regions with relatively few O-glycosylation and N-glycosylation sites (Bell et al., 
1980), and with a high proportion of cysteine (>10%). Domains at the C- and or N-
termini of mucin polypeptides have homology with domains within von Willebrand 
factor (Cao et al., 1999), and are important for the disulfide-mediated polymerization 





Figure 1.4 The structure of mucin. The protein backbone (apomucin) consists of an NH2-terminal 
domain (blue), central domain with a high number of tandem repeat (TR) domains that contain proline 
and are high in serine and/or threonine residues (yellow), and a COOH-terminal domain (green). 
Numerous O-glycans are attached to threonine or serine residues in the TR domains (reproduced from 

















1.7 Mucin O-glycans   
 
More than 30 glycosyltransferases have now been identified, of which at least a dozen 
participate in the synthesis of mucin O-glycans (Toki et al., 1997). In addition to N-
acetylgalactosamine, mucin oligosaccharides also contain N-acetylglucosamine, 
galactose, fucose, sialic acids, and traces of mannose and sulphate. Terminal sugars, 
sialic acid and sulfates on Gal or GlcNAc, impart negative charges to mucins which 
account for their low pI values, whereas fucose imparts hydrophobicity (Allen, 1989; 
Forstner and Forstner, 1994; Corfield et al., 1995). The glycan chains are clustered in 
specific, large, central domains and confer important structural and biological 
properties to the molecules, including protease resistance, pathogen sequestration, and 
ion and water binding. These properties are important for the formation, rheological 














Figure 1.5. Diagrammatic representations of the five types of mucin O-glycans. O-glycan chains 
are synthesized by specific glycosyltransferases in a stepwise manner following transfer of GalNAc to 
a serine or threonine, elongated by addition of Gal or GlcNAc. The monosaccharide composition of 
mucins is comprised of five sugar residues namely: N-acetylglucosamine, N-acetylgalactosamine, 
galactose, fucose and sialic acid. Mucin can be terminally glycosylated by addition of fucose, sialic 














1.8 Proteolysis and reduction of mucin 
 
Mucins are heavily glycosylated and play a major role in the protection of the 
epithelium from chemical and mechanical aggressions (Gum et al., 1992; Strous and 
Dekker, 1992; Lesuffleur et al., 1994; Gendler and Spicer, 1995). Polymeric mucin 
from a variety of sources are made up of multiples of subunits (Figure 1.6) linked 
together into linear arrays (Harding et al., 1983) to give the macroscopic mucins. 
Mucin subunits are linked together by disulfide bridges and these are susceptible to 
reductive disruption by thiols such as 2-mercaptoethanol or dithiothreitol (DTT) 
(Figure 1.6). The thiol reduction products are commonly referred to as ‘subunits’. 
Regions of low or no glycosylation are prone to proteolysis by enzymes such as 
trypsin. The digestion products that result are commonly referred to as ‘T-domains’ 
(Figure 1.6). The glycoslyated mucin domain has limited sites of access for 
proteinases. Proteolytic enzymes and mucolytic drugs (e.g. N-acetylcysteine) dissolve 
the mucus gel (mucolysis), hydrolysing regions of accessible, non-glycosylated 













































Figure 1.6. Diagrammatic representation of mucin proteolysis. (A) The whole mucin composed of 
three subunits linked together via disulfide bonds located on sparsely glycosylated N- and C-terminus. 
(B) Subunit obtained after reduction of disulfide bond and (C) carbohydrate side chains in the 
glycosylated region protect mucins from proteolysis (reproduced from Carlstedt et al., 1983). 
 
 
1.9 Mucin genes and classification 
 
Mucin genes are independently regulated and their expression is organ-, tissue-, and 
cell-specific (Gambus et al., 1993; Ho et al., 1993, 1995; Lesuffleur et al., 1994). 
There are three classes of mucins which differ in biological structure and cellular 
location; those which are bound to the membrane (monomeric), those which are 
secreted and form extracellular gels (oligomeric) and those that are secreted and do 
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not form gels (soluble). Members from each family possess common characteristics 
(Figure 1.7). 
 
MUC1, MUC3A, MUC3B, MUC4, MUC11, MUC12, MUC13, MUC16, MUC17, and 
MUC20 mucins have transmembrane domains in their carboxy terminus and are 
referred to as cell-tethered mucins (Dekker et al., 2002; Swallow et al., 1987; Gendler 
et al., 1990; Gum et al., 1990; Rose and Voynow, 2006) or trans-membrane mucins 
(Figure 1.7). 
 
Secretory mucins are further subdivided into those that are cysteine rich and those that 
are cysteine-poor. MUC2, MUC5AC, MUC5B, MUC6 and MUC19 are large secretory 
mucins with cysteine-rich motifs while MUC7, MUC8 and MUC9 are non-polymeric 
mucins lacking the cysteine motifs. MUC14, MUC15 and MUC18 do not have tandem 
repeats and remain unclassified (Godl et al., 2002; Lidell et al., 2003; Moniaux et al., 
2001; Rose and Voynow, 2006). 
 
1.9.1 Membrane-bound mucins 
 
Membrane-associated mucins are bound by a transmembrane domain directly to the 
bilayer of a membrane (Figure 1.7). They serve as molecular sensors of the molecular 
environment at the cell surface, communicate information about the morphological 
condition or the differentiation status of the cell and signal the status of interaction 
between mucins and associated ligands and receptor (Hollingsworth and Swanson, 
2004). They communicate information about the extracellular status via an 
intracellular signal transduction and associate with the secreted mucin layer by 
covalent and non-covalent bonds. 
 
MUC1 is located on chromosome 1q21-q24; MUC3A, MUC3B, MUC11, MUC12 
and MUC17 on chromosome 7q22; MUC4 and MUC20 on chromosome 3q29; 
MUC13 on chromosome 3q13.3 and MUC16 on chromosome 19q13.2 (Rose and 
Voynow, 2006). MUC1 is expressed in most epithelial tissues, including the breast 
and pancreas, as well as in the gastrointestinal, respiratory and urinary tracts (Zotter et 












1.9.2 Secreted and gel forming mucin (polymeric) 
 
Genes for gel forming mucins MUC2, MUC5AC, MUC5B, and MUC6 are located in 
a gene complex on chromosome 11p15.5 (Gum et al., 1989; Winterford et al., 1999; 
Toribara et al., 1993; Pigny et al., 1996; Gendler and Spicer. 1995). The MUC19 gene 
is located on chromosome 12q12 (Rosseau et al., 2008). There is very little data 
available on MUC19, which is expressed in the submucosal glands of the trachea 
(Rosseau et al., 2008). Only MUC2, MUC5AC, MUC5B, and MUC6 contain the 
cysteine-rich motifs in their C- and N-terminal domains necessary for disulfide-
mediated polymer formation critical for the gel-forming properties of these 
macromolecules (Desseyn et al., 1998; Toribara et al., 1997). These domains are very 
similar to that of von Willebrand factor (Desseyn et al., 1998). The covalent 
polymerisation (characteristic of secreted mucin) of the mucin molecules end to end 
through disulphide bridges is essential for mucins to form a gel (Allen and Pearson. 
1993; Carlstedt et al., 1983).  
 
MUC2 is the first human secretory mucin gene to be cloned and completely 
sequenced (Gum et al., 1989, 1992). It is a major component of intestinal mucus gel 
secretions (Corfield and Gough, 1995) and is considered an insoluble mucin 
biochemically (Axelsson et al., 1998). MUC5B has the largest central tandem repeat 
region (Desseyn et al., 1997), among known mucins. It is the main gel forming mucin 
in saliva and one of the two major mucins of the respiratory mucus. MUC5AC and 
MUC6 are secreted into the stomach.  
 
1.9.3 Secreted and non gel forming mucins (soluble)  
 
Two genes fall into this class: MUC7 on chromosome 4q13.3 (Bobek et al., 1993) and 
MUC8 on chromosome 12q24.3 (Shankar et al., 1997). MUC7 is a small, secreted 
mucin that lacks cysteine-rich domains (does not form gels) while MUC8 is a large, 
secreted mucin that lacks the von Willebrand factor D4 or C1 and C2 domains 
typically present in the carboxyl end of large secretory mucins (Dekker et al., 2002). 
There is little information on the MUC8 glycoprotein. However, MUC7 has been well 
characterized, particularly in saliva. The N terminus of MUC7 contains a histatin-like 

















Figure1.7 Diagrammatic representation of three classes of mucins. Blue squiggles represent O-
linked oligosaccharides. With the exception of MUC13, mucins extend much farther due to their 
extended 3D structures contributed by the proline-rich heavily O-glycosylated tandem repeat domains. 
MUC1 and MUC4 are the largest transmembrane mucins, extending >200 nm from the cell surface. 
The ectodomain structures of MUC16 and MUC17 are considerably shorter than those of MUC1 and 
MUC4, but still much larger than other surface glycoproteins. Secreted mucins, such as MUC2, 
MUC5AC, MUC5B and MUC19 are even larger, reaching 500–1000 nm in length. (Reproduced from 
Brayman et al., 2004) 
 
1.10 Gastric mucin 
 
Mucus of which mucin (mucous glycoprotein) is the gel forming component in the 
stomach protects the epithelium against acid and pepsin in the gastric juice, against 
exogenous damaging agents (pathogens, drugs), and mechanical damage (Bell et al., 
1985; Allen et al., 1986).  Normal gastric mucosa expresses MUC1, MUC4, 
MUC5AC, and MUC6 (Audie et al., 1993; de Bolos et al., 1995; Ho et al., 1995; 
Byrd et al., 1997; Reis et al., 1997), with MUC1, MUC5AC, and MUC6 being the 
most prominent (Ho et al., 1995). Other mucins are generally absent from the normal 















In the stomach, there is a separation of the regions of mucin production (Figure 1.8). 
Mucins present in the antrum are different from those in the body region (Ohara et al., 
1986). There is evidence that the two polymeric mucins, namely MUC5AC (surface) 
and MUC6 (glands) remain distinct within the mucus gel (Ho et al., 2004; Nordman 
et al., 2002). MUC1 is widely expressed in mucous cells of the surface epithelium, 
and is focally expressed in oxyntic glands and parietal cells of the body and in the 
pyloric glands of the antrum (Burchell et al., 1987; Girling et al., 1989; Ho et al., 
1993, 1995; Walker et al., 1995; Reis et al., 1998, 1999). MUC5AC is highly 
expressed in foveolar and neck cells of the body and the antrum (de Bolos et al., 
1995; Ho et al., 1995; Byrd et al., 1997; Reis et al., 1997). MUC6 is expressed in 
mucopeptic cells of the neck zone of the body region of the stomach and in pyloric 
glands of the antrum (de Bolos et al., 1995; Tajima et al., 2001; Ho et al., 1995, 2000; 
Byrd et al., 1997; Reis et al., 1999, 2000; Audie et al. 1993). 
 
This characteristic cell- and tissue-specific distribution of mucin expression observed 
in the gastric mucosa may be related to the specific function of each mucin (de Bolos 
et al. 1995; Ho et al. 1995; Byrd et al. 1997). Glycosylation differences between 
gastric mucins isolated from the surface epithelium and the glands have also been 
shown (Nordman et al., 2002).  Therefore, in the stomach, it is possible that the two 
gel layers, the firmly adherent and that removed by shear, are two different mucin 
gene products (MUC5AC and MUC6) or different mixtures of two gene products, 


















Figure 1.8. Diagrammatic representation of the stomach showing the different regions. (1) 
Cardia; (2) Fundus; (3) Body [MUC5AC, MUC1, MUC6] (4) Antrum and pylorus [MUC5AC, MUC1, 
MUC6] (reproduced from Marques et al., 2005) 
 
1.11 Gastric mucin: Protection against acid 
 
The gelation of mucin is complex, involving the interplay of electrostatic and 
hydrophobic interactions. At neutral pH of 6–7 the non-glycosylated Cys-rich regions 
of mucins are in conformation with the hydrophobic domains. At acidic pH 2 the 
hydrophobic regions of protein are exposed (Figure 1.9). The hydrophobic domains 
on adjacent molecules are then able to associate and cross-link with mucin to form a 
stable adherent mucus gel. Bromberg and Barr. (2000) reported that the non-
glycosylated regions of mucins were involved in the aggregation of human 
tracheobronchial mucin. The entanglement of the sugar side chains further contributes 
to the high viscosity of mucin solutions (Figure 1.9). 
 
Only the firmly adherent layer is important in maintaining pH at a neutral level during 
luminal acid exposure (Phillipson et al., 2002). Thus the combination of the firmly 
adherent mucus layer and HCO3
- secreted from the surface epithelial cells maintain a 
neutral pH on the surface of the epithelial cells even though the luminal pH is acidic 













































Figure 1.9 A diagrammatic representation of the protective mucus layer of the stomach and pH 
induced gelation. The breaking of electrostatic interactions around pH 4 and below produce a 
conformational change in pig gastric mucin from a random coil to a rod (or stiff worm-like chain) and 
lead to gelation at high concentrations and at low pH by exposing hydrophobic regions which are 
folded and thus sequestered in the interior at neutral pH (reproduced from Bhaskar et al., 1992 and 
www.science.org.au/nobel/2005/05diagram3.htm). 
 
1.12 Gastric mucin and trefoil peptides 
 
Although mucins are the major molecular constituents of mucus, the secretion 
contains a host of other proteins as well as non-protein components and water as the 
main component (Creeth, 1978). One of the important roles for mucus is the retention 
of these non-mucin-secreted molecules in the immediate extracellular environment. 
There is evidence that some non-mucin proteins are either covalently or non-
covalently associated with the extracellular mucin complex (Thornton et al., 2001; 
Wickstrom et al., 2000; Thim, 1997). These molecules may become associated with 
mucins during biosynthesis or packaging into secretory granules and remain integral 
Mucin in random coil conformation, pH>4 













components of the secreted mucin complex, whereas other molecules may be co-
secreted before becoming associated with the mucin complex.  
 
Within the gastrointestinal tract, trefoil peptides and mucins are coexpressed in 
mucous cells in a closely related manner (Poulsom and Wright et al., 1993; Thim et 
al., 2002; Kjellev et al., 2006; Wright et al., 1997). Trefoil peptides are localised 
within mucin granules in mucous secreting epithelial cells (Ahnen et al., 1994). 
Individual trefoil peptides are uniquely associated with specific mucin glycoproteins, 
possibly essential for mutual functional roles (Ahnen et al., 1994). 
 
TFF1 (pS2) is localised in the mucus producing superficial epithelial cells throughout 
the normal stomach (Rio et al., 1988; Hanby et al., 1993) and has been shown to be 
co-expressed with MUC5AC (Madsen et al., 2007; Ruchaud-Sparagano et al., 2004) 
Similarly, TFF2 or spasmolytic peptide (SP) is found in mucous neck cells and deep 
pyloric glands (Hanby et al., 1993; Jeffrey et al., 1994), co-expressed with MUC6. 
TFF3 or intestinal trefoil factor (ITF) is expressed predominately in the goblet cells of 
the small and large intestine (Suemori et al., 1991; Podolsky et al., 1993). 
 
Non-mucin glycoproteins and proteins play key roles in mucosal protection and 
mucus organization. Tomasetto et al. (2000) showed that TFFs interact with the 
secreted gel forming mucins through binding with their cysteine-rich domains. 
Studies using TFF1 knockout mice revealed dysfunctional gastric mucus production; 
the mice developed gastric adenomas, and one third of them developed neoplasia 
(Lefebvre et al., 1996). Thus trefoil peptides, together with their pattern of 
distribution and co-production with mucus in the gut, are involved in mucosal 
protection and repair (Kindon et al., 1995; Playford et al., 1995; Babyatsky et al., 
1996). 
 
1.13 Gastric mucin and H. Pylori 
 
Helicobacter pylori, a gram-negative bacteria, is adapted to life in the mucus of the 
digestive tract of vertebrates. The acidic milieu in the stomach is lethal to most 
bacteria, but H. pylori not only survives but actually colonizes the stomach in 50% of 











the polyvalent presentation of receptor analog structures, mucins are capable of 
binding bacteria through specific attachment sites (Schroten et al., 1992; Kubiet et al., 
2000; Reddy et al., 1996).  The expression patterns of gastric mucins MUC5AC and 
MUC6 are altered as a response to colonization (Byrd et al., 1997, 2000).  
 
The most comprehensive example of how mucin glycans protect the epithelium from 
pathogens is highlighted by the dual role of MUC5AC and MUC6 mucins in the 
defense of the gastric epithelium from H. pylori. The blood group Leb 
oligosaccharides associated with MUC5AC are the primary receptor for H. pylori in 
the human (Van de Bovenkamp et al., 2003; Linden, 2002) and compete with the 
bacterium for binding to similar ligands on the epithelial cell surface, whereas 
terminal α1–4-linked Nacetylglucosamine residues carried on MUC6 function as an 
antibiotic (Kawakubo et al., 2004). Sialylated Lewis antigens contribute to H. pylori 
binding in inflamed tissue (Mahdavi, et al., 2002). H. pylori positive patients exhibit 
an increase in MUC6 in surface mucous cells with a reduction in MUC5AC (Byrd et 
al., 1997). Reversal of the normal gastric pattern is corrected on elimination of 
infection (Byrd et al., 1997). H. pylori has been shown to reduce the rate of renewal 
of the loosely adherent mucus layer (Atuma et al., 1998).  
 
H. pylori in humans are associated with gastritis, gastric ulceration, gastric 
adenocarcinoma and lymphoma of mucosal-associated lymphoid tissue (MALT 
lymphoma) (Morgner et al., 2000). Its presence increases the risk of developing 
gastric cancer by 2–3-fold (Uemura et al., 2001). Ilver et al. (1998) showed that there 
is a higher susceptibility to H pylori infection in individuals of O and Leb blood 


























Figure 1.10. Diagrammatic representation of mucin- H. pylori interactions. H. pylori are Gram-
negative, spiral-shaped microaerophilic bacteria that are involved in several gastric diseases. Binding 
occurs both to secreted and membrane-associated mucins. The mucin oligosaccharide diversity 
enhances the possibility that bacteria bind to mucus, thus facilitating their removal. By providing 
competing receptors for cell-surface glycoconjugates, mucins may trap bacteria and make them less 
successful in their attempts to colonize the epithelium. Thus, the array of oligosaccharides expressed on 
the mucins of an individual may play a key role in governing the susceptibility to infection. 
(reproduced from Linden et al., 2004 and www.science.org.au/nobel/2005/interview.htm) 
 
 
1.14 Mucin expression in intestinal metaplasia 
 
Intestinal metaplasia (IM) of the stomach is the replacement of the gastric mucosa by 
an epithelium that histologically resembles the intestinal mucosa. The presence of 
goblet cells in the gastric mucosa is the most important single histologic parameter 
that characterizes intestinal transformation. Epidemiological and long-term 
prospective studies of patients with chronic gastritis and IM have provided strong 
evidence of a link between IM and intestinal-type gastric carcinoma (You et al., 1999; 
Morson and Sobin, 1980; Correa, 1988; Chejfec et al., 1992; Imai and Murayama, 












Intestinal metaplasia is classified as complete (small intestinal or type I) and 
incomplete (colonic or types II and III). Specific subtypes of IM can be identified 
based on mucin secretion (Jass and Filipe, 1981; Jass, 1980).  
 
The complete (type I) is characterized by the goblet cells secreting sialomucins and 
the incomplete type (encompassing types II and III) is characterized by the presence 
of columnar and goblet cells secreting sialo and/or sulfomucins. Mucins with O-
acetylated sialic acids (O-acetylsialomucins) are not seen in type III IM but are 
observed in complete or type I IM (Filipe and Ramachandra, 1995; Jass and Roberton, 
1994). Several studies have shown that type III intestinal metaplasia is associated with 
an increased risk of malignant transformation (Filipe et al., 1994).  
 
The repertoire of mucins synthesized by gastric carcinoma cells is tightly associated 
with their differentiation program. Altered mucin expression patterns have been 
reported in intestinal metaplasia, including under-expression of MUC1, MUC5AC, 
and MUC6 and increased expression of MUC2 (Ho et al., 1995; Filipe et al., 1996; 
Reis et al. 1998). The complete form of IM (type I) contains the intestinal-type MUC2 
in goblet cells. Incomplete variants (types II and III) exhibit MUC1 and MUC5AC in 
both goblet and absorptive cells and a mixture of MUC2 and MUC5AC and/or MUC6 
(Reis et al., 1999). Clinical and epidemiological observations, including follow-up 
studies indicate that the natural history of the process goes in the opposite direction: 
complete (type I) intestinal metaplasia may evolve to incomplete metaplasia (type III) 
(Silva et al., 1990; Filipe and Ramachandra, 1995; Jass and Roberton, 1994). 
 
Other markers for IM include sulphated carbohydrate antigen 91.9H (Ohe et al., 
1994), FU-MK-1 (Watanabe et al., 1993), blood-group antigens (Sakamoto et al., 
1989) and sialyl Tn and T (Carneiro and Santos et al., 1994). Other important genes in 
the development of IM include TFF3, the goblet cell-associated trefoil factor that is 
induced in the stomach early in the development of IM in both humans and rats 
(Taupin et al., 2001) that has recently been shown to be induced by Sonic hedgehog, a 
parietal cell morphogen, the expression of which is lost in IM in humans (van den 
Brink et al., 2002). Indeed, atrophic gastritis, especially parietal cell loss is likely to 












1.15 Gastric cancer 
 
Gastric cancer is the second most common cause of cancer-related death worldwide 
(Parkin et al., 2001; 2005). Histologically, human gastric carcinomas have been 
classified into two major groups: the intestinal type/well differentiated and diffuse 
types/poorly differentiated (Jarvi and Lauren, 1951; Lauren, 1965).  
 
Generally, the intestinal-type cancers, surrounded by IM, behave more passively than 
diffuse-type cancers (Davessar et al., 1990). On the other hand, diffuse-type gastric 
carcinomas are composed mainly of tumor cells displaying gastric differentiation 
(Reis et al., 2000; Lopez-Ferrer et al., 2000) and show poorer survival compared to 
intestinal-type carcinomas. Mucinous carcinomas are marked by exuberant pools of 
mucin production and signet ring cell carcinoma, a rare subtype, is characterized by 
intracellular mucin accumulation.  
 
1.16 Mucin alterations in gastric carcinoma  
 
Alterations in mucin expression such as the pattern of loss of mucin expression, 
increased mucin heterogeneity, and changes in glycosylation including exposure of 
simple mucin-type carbohydrates have been reported in gastric carcinomas with 
suggestions that these mucin alterations can be regarded as “molecular” markers of 
malignant transformation of the gastric mucosa. (Bara et al., 1993; Gambús et al., 
1993; Ho et al. 1993, 1995; Carrato et al., 1994; Reis et al., 1997, Sakamoto et al., 
1997; Baldus et al., 1998; Carneiro et al., 1994; David et al., 1992; Mitsuuchi et al., 
1999). These changes may have an impact on cell growth regulation, immune 
recognition, and cellular adhesion, that in turn may influence the invasive and 
metastatic capabilities of a tumour (Bresalier, 1991; Mannori et al., 1995).  
 
In normal gastric tissues, the type of mucin expressed is closely associated with the 
cell phenotype: MUC5AC is associated with foveolar cells and MUC6 with glandular 
cells. Gastric carcinomas have been found to contain a higher level of MUC1 
expression than normal gastric mucosa and de novo expression of MUC2 (Ho et al., 
1995; Lee et al., 2001; Pinto-de-Sousa et al., 2002; Baldus et al., 1998). In contrast to 











gastric carcinogenesis (Ho et al., 1995; Reis et al., 2000; Pinto-de-Sousa et al., 2002; 
Baldus et al., 1998). 
 
MUC1 is the best known mucin antigen associated with malignant progression in 
gastric carcinomas (Yonezawa and Sato, 1997). MUC1 reactivity has been shown to 
be significantly enhanced in carcinomas exhibiting tubular/papillary or intestinal 
differentiation compared with signet-ring cell or diffuse types (Baldus et al., 1998). 
The co-expression of MUC1 and MUC5AC results in increased metastatic potential 
of gastric carcinoma cells (Ho et al., 1995; Taylor, 1998). Populations at high risk of 
gastric cancer have been identified on the basis of the polymorphisms of the MUC1 
and MUC6 genes. Shorter alleles of these two genes identify genotypes at increased 
risk of gastric neoplasia (Garcia et al., 1997; Vinall et al., 2002).  
 
The expression of MUC5AC has significantly been shown to associate with 
carcinomas that usually display a “gastric” differentiation (Fiocca et al. 1987; 
Carneiro et al. 1992; Reis et al. 1997). MUC5AC was reported to correlate with 
infiltrative growth patterns (Pinto-de-Sousa et al., 2002) associated with diffuse-type 
carcinoma (Pinto-de-Sousa et al., 2002; Gurbuz et al., 2002), which are characterized 
histologically by discohesive cells and the common presence of signet ring cells. 
Therefore, it would be expected that MUC5AC positive tumours have a worse 
prognosis than MUC5AC negative tumors. Kocer et al. (2004) reported that 
MUC5AC-positive tumours correlated with poor clinicopathological parameters and 
decreased overall survival. In contrast, Baldus et al. (2002) and Pinto de-Sousa et al. 
(2002) observed significantly better survival in patients who retained MUC5AC in 
their tumours. 
 
MUC2 appears to be a hallmark of the mucinous type of gastric carcinoma (Reis et 
al., 2000; Lee et al., 2001; Pinto-de-Sousa et al., 2002, Gurbuz et al., 2002; Kocer et 
al., 2004). Mucinous carcinoma is defined as an adenocarcinoma in which a 
substantial amount of mucin (more than 50% of the tumour) is retained within the 
tumour (Jass and Sobin, 1989). Detection of MUC2 in gastric carcinoma is an 














Figure 1.11. Mucin alteration in gastric carcinoma. An important feature of carcinoma is an altered 
biosynthesis of the carbohydrate structures on mucin. Cancer cells frequently exhibit incomplete 
glycosylation, which results in the synthesis of short oligosaccharides and hence the exposure of 
cryptic core region oligosaccharides and apomucin. (reproduced from 
www.merckoncologycol.com/medicos/brochure.htm) 
 
1.17 Mucin and cell adhesion 
 
Invasiveness and metastasis are the most important characteristics of malignant 
tumours and associated with mortality. Recently, many tumour makers have been 
identified which are used not only for diagnosis but also for the assessment of 
aggressiveness and the prognosis of tumours (Duraker and Celik, 2001). One such 
marker is MUC1, a membrane-bound mucin assumed to play various roles in tumour 
immunology, and involved in cell adhesion especially by interaction with β-catenin 
and the cell–cell contacts involving epithelial integrins (Wesseling et al., 1995) 
(Figure 2). 
 
The abnormal expression of E-cadherin and MUC1 has been shown in malignancy 
(Kimura et al., 2000; Tanaka et al., 2003, Zhang et al., 2004). MUC1 contributes to 
tumour invasion via the impairment of E-cadherin (Kondo et al., 1998; Ligtenberg et 
















adhesion molecule, because of its large extended and rigid structure (Figure 1.12) that 
inhibits cell-cell adhesion, inducing the release of cells from the tumour (Ligtenberg 
et al., 1992; Makiguchi et al., 1996) thus enhancing metastasis. Therefore, the pattern 
of abnormal E-cadherin and MUC1-positive expression could be an unfavourable 
marker in a patient with advanced gastric cancer. 
 
Mutations in the E-cadherin gene are associated with diffuse-type gastric cancer (Berx 
et al., 1998). A single amino acid substitution in the extracellular domain of E-
cadherin has been shown to result in functional consequences for cell adhesion 
(Handschuh et al., 2001). 
 
 
Figure 1.12. A diagrammatic representation of MUC1 interaction with structural proteins at 
cadherin-based adherens junction. MUC1 exerts anti-adhesive effects and is involved in signalling 
cascades. The cytoplasmic tail of MUC1 binds to actin filaments and in cancer cells interferes with 
cell-adhesion. Anti-adhesive effects can also be exerted by an inhibition of the integrin-mediated cell 
adhesion complex. The binding of MUC1 to β-catenin via a peptide motif in the cytoplasmic domain is 
regulated by various proteins including c-src tyrosine kinase and epidermal growth factor. The binding 
of MUC1 to β-catenin can represent an important downstream effect in tumour biology. (reproduced 



















1.18 Mucin and immunity 
 
MUC1 is frequently over-expressed in carcinomas showing invasive growth and 
results in poor prognosis in patients with gastric cancer (Ho et al., 1993; Baldus et al., 
1998; Utsunomiya et al., 1998; Kocer et al., 2004). 
 
It has been shown that an over expression of MUC1 on the membrane of cultured 
cells inhibit interaction between cytotoxic lymphocytes and tumor cells (van de Wiel-
van Kemenade et al., 1993). Agrawal et al. (1998) reported that higher levels of 
MUC1 expression are correlated with immunosupression in adenocarcinoma patients.  
Loss of polarity associated with the overexpression of MUC1 in cancer cells shields 
the tumour cell from immune recognition by the cellular arm of the immune system, 
thus favouring metastases. Tumour cells expressing sialomucin have been shown to 
be less sensitive to cytolysis by human lymphokine-activated killer lymphocytes (van 
Rinsum et al., 1986; Moriarty et al., 1990). Therefore, sialylation of the MUC1 mucin 
might be related to the invasiveness of gastric cancer cells and consequently, to the 
poor survival of the patients whose tumours express the sialylated MUC1 epitope. In 
addition to the impact of MUC1 expression on invasiveness and metastasis, this 
possible immunosupression in adenocarcinomas may affect poor outcome. 
 
1.19 Mucin core glycans: Tn, sialyl-Tn and T epitopes 
 
Mucins produced by diseased epithelia especially in cancer, are often modified in 
ways that are distinct from their normal counterparts, and these alterations are 
believed to contribute to the pathogenesis and progression of these diseases. 
Neoplastic tissues frequently show aberrant glycosylation of mucins leading to the 
expression of tumour-associated carbohydrate antigens which are often comprised of 
simple mucin-type carbohydrate antigens such as Tn, Sialyl-Tn and T (Thomsen-
Friedenreich) (Hirohashi et al., 1985; Kjeldsen et al., 1988; Ho and Kim, 1991; 
Lesuffleur et al., 1994; Kim et al., 1996). 
 
In normal mucin, this disaccharide core region coexists with many other long 
oligosaccharides on the mucin polypeptide backbone which act as a cover to prevent 











mucin. However, in cancer the cryptic core region oligosaccharides are exposed 
(Figure 1.13) as a result of incomplete glycosylation synthesizing only short 
oligosaccharides (Hakomori, 1999) (Figure 1.13). 
 
The linkage GalNAc-ά-O-ser/thr, is known as the Tn antigen (Figure 1.13) and was 
first described as a tumour-associated antigen by Springer et al. (1974). Tn is 
predominantly expressed in columnar cells (Carneiro et al., 1994). Tn and T 
structures on mucin peptide cores expressed by adenocarcinomas contribute to 
adhesion, cell aggregation, invasion and metastasis (Gendler, 2001; Glinsky et al., 
2003). Thus, a prevalence of Tn antigens on a cancer cell usually denotes a highly 
aggressive and metastatic cancer irrespective of the type of organ affected. 
 
Sialyl-Tn is a mucin-associated carbohydrate antigen which is not expressed by 
normal mucus-producing cells of the stomach but becomes expressed in metaplastic, 
pre-malignant and malignant gastric tissues. Sialyl-Tn is predominantly expressed in 
goblet cells (Carneiro et al., 1994). It serves as an excellent marker of small intestinal 
mucins and is indicative of small intestinal-type differentiation in two thirds of gastric 
cancers. Addition of sialic acid forms the Sialyl-Tn antigen (Sia alpha2, 
6GalNAcalpha-O-ser/thr), identified as a tumour-associated antigen by Kjelden et al. 
(1988). Sialyl-Tn on mucin plays a role in the adhesive interaction, which involves 




















Figure 1.13 The initial step of mucin glycosylation showing Thomsen-Friedenreich epitopes.  The 
first glycan GalNAc (orange) is added by GalNAc-transferases forming the Tn antigens. Using 
GalNAc as an acceptor, Gal (red) is added by β1,3Gal-transferase to form the T antigen. Alternatively, 
GalNAc can be sialylated (purple) by sialyl-transferase to form sialyl-Tn antigen. These antigens are 
masked in normal healthy cells, covered by polysaccharides, and only become unmasked and exposed 
as a cell moves towards malignancy where the ability to synthesize the polysaccharides which normally 
cover the T-Tn antigens is often lost (reproduced from www.dadamo.com/wiki/wiki.pl/Thomsen-
Friedenreich (T-Tn) antigen). 
 
1.20 Mucin terminal glycans: Lewis and sialyl Lewis antigens 
 
Lewis antigens are carbohydrate structures (structurally related to determinants of the 
ABO blood group systems) expressed in many tissues throughout the body, especially 
in the epithelial cells of gastric mucosa. In the normal gastric mucosa, Lewisx and 
Lewisy antigens are co-localized with MUC6 in the deep glands and also expressed in 
the chief and parietal cells of the glands. Abnormal expression of MUC6 and Lewisx 
in the superficial epithelium of the stomach from H pylori infected patients has been 
described (Boren et al., 1993). Lewisx has been related to an increased risk of 
metastasis and poor prognosis in gastric cancer patients. Lewisa, Lewisb, and sialyl-
Lewisa are co-localized in the superficial cells expressing MUC5AC (de Bolos et al., 
1995).  
 
Lewisb, expressed in the surface epithelial cells (Boren et al., 1993) in a healthy 
stomach has been shown to mediate the attachment of H. pylori to the human gastric 
mucosa (Boren et al., 1993) and to MUC5AC (Linden et al., 2002), whereas 












2002). More than 80% of H. pylori strains express Lewis blood group antigens, 
Lewisx and/or Lewisy, on their lipopolysaccharide (LPS) (Appelmelk et al., 2000; 
Simoons-Smit et al., 1996).  
 
During the process of malignant transformation these antigens undergo important 
alterations (Coon and Weinstein et al., 1986; Sakamoto et al., 1989). Torrado et al. 
(1992) demonstrated that the simultaneous expression of Lewisa antigen and 
sulfomucins indicate a greater risk of pre-neoplastic progression.  
 
Sialyl-Lewis structures present on the surface of tumour cells are carried by the 
carbohydrate chains of N-glycans or O-glycans (Maemura and Fukuda 1992). High 
levels of sialylated antigens, such as sialyl-Lewisx and Sialyl-Lewisa antigens are 
carried by the abnormal mucins of cancer cells. Shimodaira et al. (1997) showed that 
sialyl-Lewisa and sialyl-Lewisx antigens on O-glycans are associated with the 
invasion of cancer cells. Borsig et al. (2001) showed that the removal of cancer mucin 
attenuated metastasis through the reduction of sialylated antigens. The expression of 
sialyl-Lewisx and sialyl-Lewisa in mucin-type O-glycans has been demonstrated to be 
highly correlated with venous invasion and lymph node metastasis (Shimodaira et al., 
1997) and is especially involved in the formation of liver and lung metastases by 
human gastric, colon, and pancreatic cancer cells (Nakagoe et al., 2002; Opolski et 
al., 1998) 
 
1.21 Objectives of this study 
 
Our laboratory (Mall et al., 1990, 1992, 1999, 2000) reported the presence of an 
albumin associated 55-65 kDa glycoprotein on 7.5%, 10% and 4-20% gradient 
polyacrylamide gel electrophoresis, extracted from crude mucus scrapings of gastric 
ulcer and cancer resection specimens and which was not present in normal gastric 
tissue. This fragment fractionated with purified gastric mucin at a density of 
approximately 1.39–1.42 g/ml in a CsCl density gradient after ultracentrifugation 
(Mall et al., 1990, 1992, 1999, 2000). In the current study, using further extensive 
SDS-PAGE analysis (12% polyacrylamide) and a better quality molecular weight 
marker, we reproduced this finding, but the size of the fragment, previously reported 











also a better separation of this fragment and albumin which appeared as a complex in 
previous studies (Mall et al., 1990, 1992, 1999, 2000). A similar finding was made by 
Hakkinen et al. (1991) who reported a structure associated with gastric mucins in 
carcinoma that could be useful as a clinical marker for gastric cancer. 
 
The primary objective of our present study was to develop a rabbit polyclonal 
antibody against the 40-50 kDa glycoprotein found to co-fractionate with mucin 
purified from specimens resected for gastric cancer. The second objective was to 
compare, by immunohistochemistry, the tissue localization and expression of the 40-
50 kDa glycoprotein with that of gastric mucins in the normal stomach, intestinal 
metaplasia and in cancer. Our final aim was to identify this glycoprotein by proteomic 

















































The University of Cape Town Research Ethics Committee approved this study (ethics 




This Chapter describes the general laboratory reagents and methods used during the 
course of this research project. Nitrocellulose membrane and dialysis tubing was from 
Kimix (Chemical and Laboratory Suppliers, SA). The ECLTM Western blotting 
detection kit was from Amersham Biosciences (Amersham UK). Monoclonal 
Armenian hamster anti-MUC1 raised against 17 amino acids 
(SSLSYTNPAVAATSANL) to the cytoplasmic tail of MUC1 was from Sandra 
Gendler (Mayo Clinic, Scottsdale, USA). Monoclonal mouse anti-MUC1 core raised 
against the tandem repeat epitope (TRPAG), anti-MUC2 raised against synthetic 
peptides NGLQPVRVEDPDGC, anti-MUC5AC raised against RNQDQGPKFMC 
and anti-MUC6 raised against synthetic peptide of the MUC6 tandem repeat sequence 
were from Novocastra (Newcastle, UK). Monoclonal mouse anti-MUC4 antibody 
raised against a synthetic peptide TSSASTGHATPLPVTD corresponding to the 
tandem repeat sequence of MUC4 and polyclonal goat anti-mouse horse radish 
peroxidise (HRPO) linked and biotinylated goat anti-Armenian hamster secondary 
antibodies were from Santa Cruz Biotechnology, Inc (Santa Cruz, California). 
Envision+® system labelled polymer-HRP anti-mouse, anti-rabbit and 3,3'-
diaminobenzidine (DAB) substrate chromogen and polyclonal rabbit anti-Human 
Albumin were from Dakocytomation (USA). 
 
Guanidinium chloride (GuHCl), caesium chloride (CsCl), pararosanaline, 3-(3-
cholamidopropyl)-dimethyl-ammonio)-1-propane-sulfonate (CHAPS), agarose, N-
ethylmaleimide (NEM), N, N’-methylenebisacrylamide, 2-mercaptoethanol, 











(APS), glycerol, N, N-dimethyl-meta-phenylenediamine-dihydrochloride (1,3), N, N-
dimethyl-para-phenylenediamine dihydrochloride (1,4), glycine, thiourea, entellan, 
urea, aminopropyl-tri-ethoxysilane (A.P.E.S), acetone and bovine serum albumin 
(BSA) were purchased from Sigma-Aldrich (UK).  
 
Phenylmethylsulfonylfluoride (PMSF), N, N, N, N’-tetramethylethylenediamine 
(TEMED), Coomassie Brilliant Blue R-250, ethylenediaminetetra-acetic acid 
disodium salt (Na2-EDTA), polyoxyethylene sorbitan monolaurate (Tween 20), 
acetone, acetonitrile, glacial acetic acid, hydrochloric acid, propan-2-ol (iso-propyl 
alcohol), magnesium sulphate, methanol, xylol, copper sulphate, citric acid, sodium 
iodate, aluminium ammonium sulphate, sodium di-hydrogen orthophosphate, 
formalin, hydrogen peroxide, folin reagent, thymol, glass slides and cover slips were 
purchased from Merck (UK).  
 
Human serum albumin (HSA) was purchased from the Western Cape Blood 
Transfusion Service (Parow, South Africa). Ampholytes and Bradford assay solution 
were purchased from BIO-RAD.  Mineral oil was purchased from GE Healthcare. 
Haematoxylin, eosin, hydrogen peroxide, hydrochloric acid (HCl), sodium 
metabisulphate, phloxine, periodic acid, acetic acid, sodium chloride, potassium 
chloride, alcian blue, potassium metabisulphite, charcoal hydrate and sodium 
bicarbonate were from British Drug Houses (BDH Chemicals Ltd). Alcohols were 
from Saarchem Chemicals (SA). Ammonium bicarbonate and trypsin were purchased 
from Promega (SA). 
 
2.2.1 Standard equipment used throughout this project  
 
A Hitachi U 2000 spectrophotometer, a Hitachi Himac high speed centrifuge, a 
Beckman L8-70m ultracentrifuge, a Christ ALPHA 1-5 freeze drier, a Hoefer SE600 
slab gel system and a Janke and Kunkel Ultra-turrax were standard items of 
equipment used throughout the project. All equilibrium density gradients were 
performed in a Beckman 60 Ti titanium rotor using polyallomer tubes (capacity 40 
ml). Pressure cooker for antigen retrieval, microtome for cutting sections, hot oven, 











machines were used for processing and embedding tissue. Leica 2000R sliding 




Mucus scrapes were obtained from 27 patients who had undergone gastrectomy (16 
partial and 11 total resections) between 2005 and 2008 from Groote Schuur Hospital 
(n=23) and the University of Cape Town Private Academic Hospital (n=4). 
Information collected from the patients’ medical and pathological records about 



































Table 1. Clinical and pathological data of patients in this study 
Lab 
number 





S1  60 M GSH Partial gastrectomy                                       
Specimen size: lesser curvature 70mm, 
greater curvature 100mm 
Signet-ring cell               
Tumour  size:  20 x  20 x 
15mm 
T2N1M0  G3 
S2  55 F GSH Total gastrectomy                                          
Specimen size: lesser curvature 100mm, 
greater curvature 220mm 
Signet-ring cell               
Tumour  size: 70 x 80mm 
T4N2M0 G3 
S3  59 M GSH Total gastrectomy                                          
Specimen size: lesser curvature 180mm, 
greater curvature 260mm 
Signet-ring cell               
Tumour  size: 70 x 50mm 
T3N2M1 G3 
S4  59 M GSH Partial gastrectomy                                       
Specimen size: lesser curvature 120mm, 
greater curvature 160m 
Signet-ring cell               
Tumour  size: N/A 
T4N2M0 G3 
S5  58 M GSH Partial gastrectomy                                      
Specimen size: lesser curvature 120mm, 
greater curvature 150mm 
Diffuse type                     
Tumour  size: 30 x 150mm 
T3N2M0 G2 
S6 59 F GSH Total gastrectomy                                         
Specimen size: lesser curvature 160 mm, 
greater curvature 365mm 
Diffuse type                    
Tumour  size: 45 x 120 x 
12mm. 
T3N2M0 G3 
S7  43 M UCT Partial gastrectomy                                       
Specimen size: lesser curvature 55mm, 
greater curvature 90mm 
Diffuse type                   
Tumour  size: 65 x 38 x 
18mm. 
T3N1M0 G4 
S8  73 F GSH Partial gastrectomy                                       
Specimen size: lesser curvature 80mm, 
greater curvature 150mm 
Diffuse type                   
Tumour  size: 150mm 
T4N0M0  G3 
S9  60 F GSH Partial gastrectomy                                       
Specimen size: lesser curvature 90mm, 
greater curvature 150mm  
Diffuse type                   
Tumour  size 450mm 
T3N0M0 G3 
S10  74 F GSH Partial gastrectomy                                      
Specimen size: lesser curvature 100mm, 
greater curvature 270mm 
Diffuse type                       
Tumour  size: N/A 
T1N0M0 G3 
S11 57 M UCT Total gastrectomy                                         
Specimen size: lesser curvature 40mm, 
greater curvature 150mm 
Diffuse type                        
Tumour  size: N/A 
T4N1M0 G3 
S12  60 M GSH Total gastrectomy                                          
Specimen size: lesser curvature 150mm, 
greater curvature 200mm 
Mixed intestinal and 
diffuse Tumour size: N/A 
T3N2M1 G3 
S13  55 M GSH Total gastrectomy                                         
Specimen size: lesser curvature 190mm, 
greater curvature 400mm 
Intestinal type               
Tumour size: 40 x 30mm 
T4N1M0           G3 
S14 53 M GSH Partial gastrectomy                                      
Specimen size: lesser curvature 80mm, 
greater curvature 140mm 
Intestinal type                     
Tumour  size: 25 x 20 x 
7mm 
T2N2M0 G3 
S15  63 M GSH Total gastrectomy                                        
Specimen size: lesser curvature 160mm, 
greater curvature 300mm 
Intestinal type                
Tumour  size: 24 x 39 x 
9mm 
T3N1M0 G3 
S16  63 M GSH Total gastrect my                                         
Specimen size: lesser curvature 120mm, 
greater curvature 200mm 
Intestinal type                
Tumour size: 90 x 90 x 
30mm 
T1N0M0            G2 
S17  67 M GSH Partial gastrectomy                                      
Specimen size: lesser curvature 65mm, 
greater curvature 70mm 
Intestinal type                 
Tumour size: 45 x 30 x 
12mm 
T2N1M0  G3 
S18  70 M GSH Total gastrectomy                                         
Specimen size: lesser curvature 45mm, 
greater curvature 85mm 
Intestinal type                
Tumour size: 41 x 45 x 
11mm 
T2N1M0  G2 
S19  63 M GSH Total gastrectomy                                         
Specimen size: N/A 
Intestinal type               
Tumour size: N/A 
T4N2M0 G2 
S20  63 M UCT Partial gastrectomy                                      
Specimen size: lesser curvature 75mm, 
greater curvature 150mm  
Intestinal type                
Tumour size: 80 x 45 x 
45mm. 
T4N1M1 G3 
S21  61 M GSH Partial gastrectomy                                      
Specimen size: greater curvature 120mm 
Intestinal type                
Tumour size: 40mm 
T2N0M0 G1 
S22  59 M GSH Total gastrectomy                                         
Specimen size: lesser curvature 120mm,  
greater curvature 150mm 
Intestinal type                     
Tumour size: N/A 
T4N1M0 G2 
S23  64 F GSH Partial gastrectomy                                       
Specimen size: lesser curvature 70mm, 
greater curvature 160mm 
Intestinal type                
Tumour size: 65 x 72 x 
6mm. 
T2N1M0  G1 
S24  67 M GSH Partial gastrectomy                                      
Specimen size: lesser curvature 105mm, 
greater curvature 130mm 
Intestinal type                     
Tumour size: 24 x 39 x 9mm 
T3N0M0 G3 
S25  51 F GSH Partial gastrectomy                                      
Specimen size: lesser curvature 70mm, 
greater curvature 140mm  
Intestinal type                     
Tumour size: 20 x 22 x 9mm 
T2N0M0           G2 
S26  60 M UCT Partial gastrectomy                                       
Specimen size: lesser curvature 90mm, 
greater curvature 130mm  
Mucinous carcinoma               
Tumour size: 20 x 30 x 6mm 
T1N1M0 G2 
S27  64 F GSH Partial gastrectomy                                       
Specimen size: lesser curvature 115mm, 
greater curvature 175mm 
Mucinous carcinoma               
Tumour size: 65 x 72 x 6mm 
T2N2M0   G3 
N/A: not available 
















2.4 Sample collection 
 
2.4.1 Collection of gastric mucus 
 
Crude mucus was obtained from resected specimens of patients with various cancers 
of the stomach. Total or partial gastrectomy specimens were provided by a surgeon 
within 20 min of a patient having undergone surgery for carcinoma of the stomach. 
The resected stomachs were opened along the greater curvature to expose the mucosal 
surface and the gastric mucus was collected by gently scraping the mucosa of these 
stomachs with two sterile glass slides. Mucus was collected into containers on ice 
containing 6 M guanidinium HCl containing a cocktail of protease inhibitors, 10 mM 
EDTA, 5 mM NEM and 1 mM PMSF pH 6.5. Specimens were then transported (on 
ice) from the operating theatre to the laboratory where further analysis was done. 
Some clinical and pathological features of the diseased stomachs are given in Table 1. 
Mucosal scrapes from human donor stomachs (used in previous gastric studies) were 
obtained from the -80°C freezer in our laboratory and used as controls. 
 
2.4.2 Collection of human gastric tissue blocks 
 
Formalin fixed paraffin wax embedded tissue blocks were obtained from the archives 
of the Division of Anatomical Pathology, National Health Laboratory Service 
(NHLS) - Groote Schuur Hospital. All resected tumours were histologically stained 
by haematoxylin and eosin and the diagnosis was confirmed by a pathologist 
(Professor D. Govender). These samples included 3 normal mucosa sampled away 
from tumour, 17 normal mucosa immediately adjacent to tumour, 13 intestinal type 
carcinomas, 7 diffuse carcinomas, 1 mixed intestinal type and diffuse carcinoma, 4 
signet ring carcinomas and 2 mucinous carcinomas. 
 
2.5 Sample preparation and solubilisation of mucus 
 
Gastric mucus samples were subjected to homogenization with a Junkel and Kunkel 
Ultra-Turrax (1 min, 9500 rev/min at room temperature) to disaggregate mucus and 
increase its solubility. After homogenisation, gastric samples were solubilised by 











following manner: samples were spun at high-speed centrifugation (Hitashi Himag 
Centrifuge) at 10 000 x g for 1 h at 4oC to remove the insoluble debris from the 
soluble mucus. After centrifugation, the soluble material was removed, and the pellet 
(if any) was re-extracted twice as described above. If an insoluble pellet still remained 
after the re-extractions, it was reduced with 10 mM DTT for 5 h in 6 M GuHCl, 10 
mM EDTA and 5 mM NEM at 37ºC. Subsequent alkylation was with 25 mM 
iodoacetamide (IAA) for 18 h in the dark. Centrifugation (10 000 x g for 1 h at 4oC) 
was then performed to recover any soluble mucus from the reduced pellet and also to 
remove and discard the remaining insoluble material. Samples were analysed 
separately for each patient. 
 
2.6 Gastric mucin purification 
 
Gastric mucus samples obtained after extraction and/or reduction and alkylation of the 
insoluble pellet were prepared for purification by adding solid caesium chloride 
(CsCl) in 4 M GuHCl to adjust the density to 1.39-1.40 g/ml (Creeth and 
Denborough, 1970). Isopycnic density gradient ultracentrifugation was performed 
twice for 48 h at 105 000 x g (Beckman L45 centrifuge). After ultracentrifugation, 
tubes were demarcated into 9 equal fractions with the top fractions (1-3) containing 
proteins and lipids, the middle fractions (4-6) containing mucins and the lower 
fractions (6-9) containing nucleic acids. The density of each fraction was determined. 
The protein and glycoprotein content of each fraction was measured after dialysis (24 
h) against distilled water to remove caesium and guanidinium chloride. The purified 
mucin fractions of each sample obtained after ultracentrifugation, were pooled, 
dialysed against distilled water and freeze dried. 
 
2.7 Analytical procedures 
 
2.7.1 Glycoprotein estimation 
 
Mucins were estimated by the periodic acid Schiff (PAS) procedure of Mantle and 
Allen. (1978). Aliquots of each fraction after caesium chloride density gradient 
ultracentrifugation were dialysed against distilled water to remove excess caesium 











Schiff reagent was then added and after 30 min the sample absorbance was read at 
555 nm. 
 
2.7.2 Protein assay 
 
After density gradient centrifugation and dialysis, the protein content of the fractions 
was determined by the Lowry assay (1951).  
 
2.7.3 Bradford assay  
 
Protein quantification was also performed using the modified Bradford assay method 
(Bradford, 1976), as modified by (Ndimba et al., 2003), using BSA as a standard to 
generate the calibration curve. The absorbance was measured at a wavelength of 595 
nm using the Genesis 5 Spectrophotometer (Milton Roy, Groton, CT, USA). 
 
2.8 Dialysis of samples 
 
Prior to any analysis or assay, the mucin rich fractions were pooled and dialysed 
overnight by constant stirring (using Spectrapore dialysis tubing prepared by boiling 
in distilled water containing 0.5% sodium bicarbonate/EDTA for 1 min) against four 
changes of distilled water at 4°C to remove GuHCl and caesium chloride salts which 
might interfere with biochemical procedures.  
 
2.9 Freeze drying 
 
Dialysed mucin samples were transferred into collecting jars which were immersed in 
liquid nitrogen and snap frozen. The jars were loaded into Virtis vacuum flasks which 
were connected to a Christ ALPHA 1-5 freeze drier and samples were freeze dried at -
54oC. Lyophilised mucins were stored at -20oC until required. 
 
2.10 One-dimensional Sodium dodecyl sulfate polyacrylamide-gel electrophoresis  
 
Freeze dried, purified gastric mucin samples (300-500 μg each) were prepared in 











glycerol, 0.01% bromophenol blue and 5% 0.2 M 2-mercaptoethanol and boiled for 2 
min prior to loading. One-dimensional (1-D) sodium dodecyl sulphate (SDS) 
polyacrylamide gel electrophoresis (PAGE) 10% and 12% (w/v) was performed 
according to the method of Laemmli (1970) using the Hoeffer Mighty Small mini-
electrophoresis system. Samples and molecular weight markers were electrophoresed 
simultaneously at a constant current of 20 mAmps per gel until the dye front ran out 
of the gel (2-3 h).  
 
2.11 Staining gels 
 
2.11.1 Coomassie Brilliant Blue R-250 gel staining  
 
After electrophoresis, gels were immersed in Coomassie brilliant blue staining 
solutions 1, 2, and 3 prepared from stock solution 1.25% (w/v) Coomassie brilliant 
blue in distilled water and heated in a microwave for about 1 minute. Gels were 
stained for about 30 min in each solution with containers shaking on an orbital shaker. 
Staining solution 1 contained 10% (v/v) glacial acetic acid, 2% (v/v) Coomassie 
stock, 25% (v/v) propan-2-ol, staining solution 2 contained l0% (v/v) glacial acetic 
acid, 0.25% (v/v) Coomassie stock, 10% (v/v) propan-2-ol and staining solution 3 
contained 10% (v/v) glacial acetic acid, 0.25% (v/v) Coomassie stock. Destaining 
solution contained 10% (v/v) glacial acetic acid, 1% (v/v) glycerol in water. Once the 
staining steps were completed, the gels were destained until the desired bands/spots 
intensity was achieved.  
 
2.11.2 Periodic acid Schiff’s gel staining 
 
After electrophoresis, gels were fixed in 50% (v/v) ethanol and oxidized in 1% (v/v) 
periodic acid made up in 3% (v/v) acetic acid, then stained with PAS and destained in 
















2.11.3 Ponceau S gel staining 
 
SDS-PAGE from which the 40-50 kDa glycoprotein was isolated for immunization 
was stained with Ponceau S (C.I. 27195) for 5 min. Gels were then immersed in 
distilled water until the high background was cleared and protein bands were visible.   
 
2.12 Isolation of the 40-50 kDa glycoprotein 
 
Gels were electrophoressed in duplicate. The first gel was stained with PAS to 
highlight the presence of the 40-50 kDa glycoprotein and the second with Ponceau S 
from which the glycoprotein was cut. The 40-50 kDa glycoprotein was cut as a band 
just below albumin and between Mr 40 and 50 kDa. 
 
2.13 Antibody production 
 
Immunization was carried out as described by Bellstedt et al. (1987). In brief, a three 
month old female rabbit was immunized intravenously with the 40-50 kDa 
glycoprotein complexed to acid-treated Salmonella minnesota R595 bacteria so that 
the ratio by dry mass of protein to bacteria was 1 to 5. The amount of 240 µg (40 µg 
of protein and 200 µg of naked bacteria) of the complex used at every immunization 
was suspended in 0.5 ml PBS and injected intravenously in the peripheral ear vein. 
The rabbit was immunized on days 1, 4, 7, 14, 17, 21, 28, 31 and 35 respectively. 
Boosts consisting of 3 immunizations within a week of the same amount of protein 
naked bacteria complex were administered intravenously in order to collect more 
serum. Blood (2.0 ml) was drawn from the central ear artery using a syringe prior to 
immunization as a negative control. Blood (2.0 ml) was drawn on day 28 to test 
whether the animal was responding. On day 42 when optimal antibody production 
was routinely achieved using this method, 24.0 ml of blood was drawn. A week after 
boosts, blood was drawn again (24.0 ml). The blood was allowed to clot, centrifuged 
and the antiserum separated from the blood. Antiserum was stored at -18ºC. Antibody 














2.14 Dot blot 
 
Mucin samples (crude and purified) and Bovine Serum Albumin in sample loading 
buffer were applied directly onto a nitrocellulose membrane. Samples were then 
vacuum blotted at pressure 40-50 bars for 1 h. Membranes were probed with anti-(40-
50 kDa glycoprotein) antibody and the respective secondary antibody (goat anti-rabbit 
HRP). Detection was carried out using an ECL kit. 
 
2.15 Western blotting 
 
The reactivity of the polyclonal rabbit anti-(40-50 kDa glycoprotein) against the 
antigenic 40-50 kDa glycoprotein was determined by western blot. Gastric samples 
purified from cancer resected specimen were electrophoresed in both 10% and 12% 
(w/v) SDS-PAGE, and then transferred onto nitrocellulose membranes 
(Nitrocellulose, 0.22 Micron) using a transfer buffer containing 192 mM glycine, 25 
mM Tris, 1.3 mM SDS and 20% (v/v) methanol and a semi-dry electroblotting unit at 
0.8mA/cm2 for 1h. After electro-blotting, non-specific binding was blocked by 
incubating the membranes in 5% (w/v) low fat milk powder in TBS, 0.05% (v/v) 
Tween-20 (TBST) at 4oC for 1h. The membranes were then washed with TBST (3 × 5 
min) and probed for 1 h with rabbit anti-(40-50 kDa glycoprotein) antibody.  
 
The anti-(40-50 kDa glycoprotein) antibody was prepared in two ways, one with 
Human Serum Albumin (HSA, 20% (v/v) protein solution) and one without. The 
antibody was diluted in TBST and incubated with Human Serum Albumin in a 1 : 500 
dilution at 37°C for 1 h. The cocktail was adjusted to a final dilution of 1 : 5000 with 
5% (w/v) low fat milk powder made up in TBST. The membranes were washed (3 × 5 
min) with TBST and incubated for 1 h with HRPO linked secondary antibody to goat 
anti-rabbit diluted in 5% (w/v) low fat milk powder in TBST at dilutions of 1 : 5000. 
After another TBST wash (3 × 5 min), bands were detected using an Enhanced 

















2.16.1 Sample preparation 
 
Formalin fixed paraffin wax embedded gastric tissue blocks were cut to 2 µm sections 
on a sliding microtome. These blocks were matched to the patients that had mucus 




All the sections (2 µm) from paraffin wax embedded tissue blocks were stained with 
haematoxylin and eosin (H&E) as routine stain for morphology and diagnosis. 
Selected sections were stained with periodic acid-Schiff (pH 2.5)/Alcian blue 
(PAS/AB) to identify neutral mucins and sialomucins and with high iron 
diamine/alcian blue (HID/AB) to identify sialomucins and sulfomucins. Intestinal 
metaplasia was classified according to Filipe and Jass. (1986) as follows: complete 
(Type I) with mature absorptive cells (neutral mucins) and goblet cells (sialomucins); 
incomplete (Type II) with few or no absorptive cells (neutral and sialomucins) and 
goblet cells (sialomucins or little sulfomucins, or both); and incomplete (Type III) 
with columnar cells (predominantly sulfomucins) and goblet cells (sialomucins, 
sulfomucins, or both). All the slides were assessed with the assistance of a chief 




Tissue sections (2 µm) cut from paraffin wax embedded tissue blocks matched to the 
patients that had mucus scraped from their stomachs were fixed onto APES (amino-
propyl-tri-ethoxy-silane) coated glass slides overnight in an incubator at 55ºC. 
Sections were dewaxed in xylol and rehydrated through descending graded alcohols 
to distilled water. Endogenous peroxidase was blocked by treating slides with 3% 
(w/v) hydrogen peroxide/methanol solution for 15 min. Heat-mediated antigen 
retrieval using citrate buffer (0.01 M, pH 6.0) was performed in a Presto pressure 











pressure for sections probed with the respective mucin antibodies. No retrieval was 
applied for sections probed with anti-(40-50 kDa glycoprotein) antibody.  
 
Non-specific binding for all antibodies was blocked with non-immune normal goat 
serum for 10 min (1 : 20) followed by optimally diluted primary antibody (Table 2) 
and the respective secondary antibody (Envision). Tissue sections fixed onto APES 
coated slides were incubated with primary rabbit anti-(40-50 kDa glycoprotein) 
polyclonal antibody, mouse anti-human monoclonal antibodies to (MUC1, 
MUC1core, MUC2, MUC4, MUC5AC and MUC6) and rabbit anti-human-albumin 
polyclonal antibody. The antibodies used in this study and their specificities are listed 
in Table 2. The anti-(40-50 kDa glycoprotein) antibody was diluted in PBS and HSA 
(1 : 500) and incubated at 37°C for 1 h. All mucin antibodies were diluted in PBS.  
 
All batches included a negative reagent control and a negative as well as positive 
tissue control. For negative reagent control, the primary antibody was either replaced 
with immunoglobulins of the same class or with PBS buffer. For negative tissue 
control, we used tissue in which expression would be negative. Selection of a positive 
and negative control tissue for the anti-(40-50 kDa glycoprotein) antibody was based 
on reviewing different tissues (breast, lung, liver, small intestine, stomach, ovary, gall 
bladder) until the optimum staining tissue was obtained for the positive control and 
not obtained for the negative control. For positive controls, small intestine tissue was 
used for anti-(40-50 kDa glycoprotein) antibody, breast cancer tissue for MUC1 and 
MUC1 core, normal colon for MUC2, normal pancreas for MUC4, normal stomach 
for MUC5AC and MUC6 and normal liver for anti-human albumin. Sections were 
then incubated with the respective secondary antibody (Envision anti-mouse and anti-
rabbit HRP) (see Table 2 for list of antibodies). 
 
Finally, sections were developed using diaminobenzidine (DAB) as a chromogen (1 
drop of DAB in 1 ml of cytomation substrate buffer) for 10 min. Sections were rinsed 
with PBS and water to remove chromogen (stop the reaction) prior to colour 
enhancement with 1% (v/v) copper sulphate for 10 min. Sections were counter stained 
with Mayer’s haematoxylin and Scott’s water for 1-2 min and dehydrated with 70%, 
96% (v/v) and absolute alcohols for 10 sec each before being cleared in xylol. Finally 











2.16.4 Scoring of immunostaining in gastric tissue 
 
A semi-quantitative analysis was performed to evaluate the expression of the 40-
50kDa glycoprotein and mucins. We examined 100 fields of each tissue (normal, 
intestinal metaplasia and cancer) at ×400 magnification and scored the proportion of 
staining as 0 (<5%) for non-stained cells, 1+ (5-25%) few positive cells; 2+ (26-50%) 
well defined areas with positive cells, 3+ (51-75%) extensive areas with positive cells 
and 4+ (>75%) most cells stained. 
 
Table 2. Antibodies used in this study 
 
Primary antibodies 
Antibody type Antigen Dilutions 
and incubation time 
Polyclonal rabbit anti-(40-
50kDa glycoprotein)  
40-50kDa glycoprotein 1 : 500 (1 h) 
Polyclonal rabbit anti-
Human Albumin 
Albumin isolated from human serum 1 : 500 (1 h) 
Monoclonal armenian 
hamster anti-MUC1 
17 amino acids to the cytoplasmic tail of 
MUC1 (SSLSYTNPAVAATSANL) 
1 : 100 (2 h) 
Monoclonal mouse anti-
MUC1core 
Synthetic peptide in tandem repeat region 
TRPAG of MUC1 core 
1 : 100 (30 min) 
Polyclonal rabbit anti-
MUC2 
Synthetic peptide NGLQPVRVEDPDG of 
MUC2 
1 : 100 (1 h) 
Monoclonal mouse anti-
MUC4 
Synthetic peptide in tandem repeat region 
TSSASTGHATPLPVTD of MUC4 
1 : 100 (overnight, 4°C) 
Monoclonal mouse anti-
MUC5AC 
Synthetic peptide RNQDQGPKFMC of 
MUC5AC 
1 : 100 (30 min) 
Monoclonal mouse anti-
MUC6 
Synthetic peptide in tandem repeat region of 
MUC6 
1 : 100 (2 h) 
Secondary antibodies 
Goat anti-armenian hamster (biotinylated) antibody 
 
1 : 400 (30 min) 
Goat anti-rabbit, HRPO linked antibody 
 
Envision (30 min) 
Goat anti-mouse, HRPO linked antibody 
 













2.17 Proteomic analysis 
 
2.17.1 Reswelling of the IPG strips 
Immobiline pH gradient (IPG) strips (7 cm; pH 3-10, BIO-RAD) were rehydrated 
overnight at room temperature in a total volume of 125 µl of rehydration buffer 
containing: 2 µl of 50% (w/v) DTT, 1.25 µl of ampholytes (pH 3-10), 100 - 200 µg of 
mucin sample solubilised in urea buffer (9 M urea, 2 M thiourea and 4% (w/v) 
CHAPS), and adjusted with urea buffer to constitute a total volume 125 µl in a 
rehydration/reswelling tray. The cover plastic was carefully removed from the IPG 
strips without damaging the gel and the IPG strip was gently laid on top of the sample 
in the tray channel with the gel side facing down and taking care to avoid trapping air 
bubbles under the strip. The IPG strips were overlaid with mineral oil in order to 
prevent drying out of the strips during the rehydration process. The strips were 
allowed to rehydrate overnight at room temperature on a perfectly horizontal surface. 
A standard temperature (20°C) was maintained as the rehydration buffer is mostly 
composed of urea. Urea at temperatures >37°C carbamolytes and at a temperatures 
<10°C crystallizes. 
 
2.17.2 Isoelectric focusing (IEF) of the IPG strips 
After overnight rehydration, the IPG strips were removed from the reswelling tray, 
rinsed with distilled and deionised water. By doing this, the excess rehydration buffer 
is removed preventing urea recrystallization, which could cause prolonged isoelectric 
focusing times and bad resolutions on the gels. The rinsed and blot-dried strips were 
then transferred to an IEF machine (EttanTMIPGphorIITM IEF machine, GE 
Healthcare, Amersham, UK) with the gel side facing upward. The IPG strips were 
once again overlaid with mineral oil and the IEF machine was programmed in a step 
















2.17.3 Two-dimensional sodium dodecyl sulphate polyacrylamide gel 
electrophoresis  
Following IEF, the IPG strips were removed, rinsed with distilled water and blotted 
on a wet filter paper. The IPG strips were then placed in a clean reswelling tray and 
equilibrated in an SDS containing buffer (6 M urea, 2% (w/v) SDS, 50 mM Tris/HCl, 
pH 8.8 and 20% (v/v) glycerol), containing 2% (w/v) DTT for 15 min. This was 
followed by a further 15 min equilibration in the same solution containing 2.5% (w/v) 
iodoacetamide instead of DTT. After the second equilibration step the IPG strips were 
removed and rinsed with 1 x SDS-PAGE running buffer. This step is essential for the 
transfer of proteins from the 1st dimension IPG strips to the 2nd dimension separation 
using the SDS polyacrylamide gel. Equilibration was followed by drying the strips 
and loading them on top of a 12% (w/v) SDS PAGE for separation of proteins 
according to their molecular mass. The IPG strips were finally overlaid with 0.5% 
(w/v) agarose sealing solution, which was allowed to solidify before the gels were 
mounted in the electrophoresis cells. Gels were run at 120 V for about 90 min (at a 
constant temperature of 25°C) until the bromophenol blue dye reached the bottom of 
the gel plates as described by Ndimba et al. (2005). Protein spots were visualized 
using Coomassie Brilliant Blue and PAS. Gels were scanned using a Canon scanner 
(CanoScan 4200F) and the BIO-RAD molecular multimager system. 
 
2.17.4 In-gel digestion of protein spots from 2-D gels 
 
Protein spots from Coomassie and PAS stained 2-D PAGE were selected and excised 
manually using a clean pipette tip or razor blade and put in 1.5 ml Eppendorf tubes. 
The gel spots were washed (2 x 5 min) in 50 mM ammonium bicarbonate. The 
solution was discarded at the end of every wash. The washing step was repeated using 
50 mM ammonium bicarbonate but this time with vortexing for 30 min. The gel 
pieces were then washed (2 x 30 min) using 50% (v/v) acetonitrile and 50 mM 
ammonium bicarbonate with occasional vortexing. This step was repeated until the 
gel pieces were completely destained. Finally, 100 µl of 100% (v/v) acetonitrile was 
added to cover the gel pieces and left on the bench top for 5 min to allow the gel 
pieces to dry. The gel pieces were completely dried using a speed vacuum drier 











µl of trypsin in 25 mM ammonium bicarbonate (10µg/ml) was added to the dried gel 
pieces and incubated at 37C for 6 h for digestion. After the incubation zip tips were 
used to clean-up the sample and the quality of digestion was estimated by Matrix 
assisted laser desorption ionisation time of flight (MALDI-TOF) instrument 
(Voyager-DETM PRO Biospectrometry TM workstation, Applied Biosciences, 
Forster City, CA, USA). After the analysis, the digestion process was stopped by the 
addition of 50 µl of 1% (v/v) TFA. The samples were left for about 3 h at room 
temperature then stored at 4C for further analysis. 
 
2.17.5 Analysis using MALDI TOF mass spectrometry 
 
Spots cut from the gel and digested with trypsin were analysed using the Matrix 
assisted laser desorption ionasation time of flight (MALDI-TOF) instrument 
(Voyager-DETM PRO BiospectrometryTM workstation, Applied Biosciences, Forster 
City, CA, USA). Spectra were externally calibrated using a peptide calibration 
standard following manufactures instructions. The peptide mixture was analysed 
using a saturated solution of α-cyano-4-hydroxycinnamic acid (CHCA) in 50% (v/v) 
acetonitrile/0.1% (v/v) trifluoroacetic acid. Peak lists of the tryptic peptide masses 
were generated from spectrum and searched against the NCBInr databases using the 
Mascot software (Matrix Science, Ltd., London, United Kingdom; 
http://www.matrixscience.com). The MALDI-TOF MS identified polypeptide, its 
respective peptide coverage and a summary of other identified proteins was recorded. 
The whole protein identification process works in collaboration with database 
searching, utilizing databases such as SWISS-Prot, TrEMBL and the non-redundant 
collection of protein sequence at the US National Centre for Biotechnology 























THE PURIFICATION OF CANCER MUCINS AND THE ANALYSIS OF THE  




The aim of the study reported in this chapter was to purify mucins from crude mucus 
scrapings of gastrectomy specimens from patients with carcinoma of the stomach, and 
then to separate the 40-50 kDa glycoprotein from the purified mucins by SDS-PAGE, 
and isolate it for the purpose of raising a polyclonal antibody to it. Mucins were 
purified by a two-step isopycnic density gradient centrifugation in caesium chloride 
(Creeth and Denborough, 1970). The gels were stained either with PAS to confirm the 
presence of the 40-50 kDa glycoprotein band or with Coomassie Brilliant Blue to 
assess the purity of these mucin samples, and with Ponceau S which would allow for 
the 40-50 kDa to be extracted and used for immunization of a rabbit. The antibody 
developed was then tested for homogeneity and cross reactivity by dot blot and 




3.2.1 Purification of gastric cancer mucin  
 
Mucins were purified by density gradient centrifugation, twice in CsCl / 4 M GuHCl 
at a density of 1.39 g/ml to remove contaminant proteins and nucleic acids (Creeth 
and Denborough, 1970; Carlstedt et al., 1983). Mucins were estimated by the PAS 
method of Mantle and Allen, (1978) and protein by the Lowry method (Lowry et al., 
1951). The purification profile in Figure 3.1, was obtained after the second spin and 
demonstrates a clear separation and purification of mucin (PAS positive) from 
contaminating proteins (Lowry positive) which were successfully removed. The 






















































Figure 3.1 Caesium chloride isopycnic density gradient purification of gastric cancer mucin. 
Crude mucus scraped from stomachs resected for cancer was dissolved in 4 M GuHCl containing 10 
mM EDTA, 5 mM NEM and 0.05% CHAPS pH 6.5 and adjusted to a density of 1.39 g/ml with 
caesium chloride. Density gradient centrifugation was for 48 h (Beckman L45 ultra-centrifuge) at 105 
000 x g (4°C). Mucin positive fractions (■) at a density (▲) between 1.37-1.42 that still associated 
with some protein (♦) (A) were pooled and prepared for the second centrifugation step. Finally 
fractions (fraction number 3 to 6) clearly free of contaminating proteins (B) were pooled, dialysed 




































































3.2.2 Characterization of the 40-50 kDa glycoprotein by SDS-PAGE 
 
Purified gastric cancer mucin samples were prepared in gel loading buffer containing 
2% SDS, 10% glycerol and 0.01% bromophenol blue. Samples were electrophoresed 
after reduction with 2-mercaptoethanol. Following electrophoresis, gels were stained 
with PAS (Figure 3.2A) to confirm the presence of mucins (Figure 3.2A, lane 1-6, 
blue arrow) and the 40-50 kDa glycoprotein (Figure 3.2A, lane 1-6, black arrow) co-
fractionating with these mucins, and with Coomassie Brilliant Blue R-250 (Figure 
3.2B), to determine the presence of protein contaminants in the purified mucin 
preparation. The molecular weights of the components were evaluated by using pre-
stained protein molecular-weight standards. 
 
High molecular weight mucin bands with a size greater than 170 kDa were seen at the 
top of the stacking and running gel (Figure 3.2A, lane 1-6, blue arrow). A band of 
albumin staining with Coomassie Brilliant Blue R-250 was seen between 66k Da and 
70 kDa (Figure 3.2B, lane 2 and 4, red arrow). Two smears were also seen below 
albumin in the region of 40-50 kDa (Figure 3.2B, lanes 2 and 4, green arrows). Low 
molecular weight protein bands below 40 kDa and 25 kDa were also seen (Figure 


























                
                               
Figure 3.2. SDS-PAGE of mucin purified from stomachs resected for cancer. Freeze-dried samples 
(300 µg in A and 60 µg in B) of purified mucin were prepared in reducing gel loading buffer and 
separated on SDS-PAGE (12%). Gels loaded with the same samples were stained with PAS (A) and 
Coomassie Brilliant Blue R-250 (B). (A and B) in the 1-D gel stained with PAS, the black arrow 
indicates the 40-50 kDa glycoprotein and the blue arrow indicates mucin purified from gastric cancer 
specimens. In the 1-D gel stained with Coomassie Brilliant Blue, the green arrows indicate the faint 40-
50 kDa protein band and the red arrow shows the band of albumin stained with Coomassie blue. Gels 
(A) and (B) contain samples in the following order: Lanes 1 (signet-ring cell carcinoma), lanes 2, 3, 5 
and 6 (intestinal type carcinoma) whilst lanes 4 (diffuse carcinoma). 
 
3.2.3 Isolation of the 40-50kDa glycoprotein by SDS-PAGE 
 
Gels were electrophoresed in duplicate under the same conditions and stained with 
PAS (Figure 3.3A) and Ponceau S (Figure 3.3B). To isolate the 40-50 kDa 
glycoprotein (Figure 3.3A lane 6, circled), the Ponceau S stained gel was cut just 
below the region where albumin was visible (Figure 3.3B lane 1, red arrow). The 
illustration of the position of albumin and the 40-50 kDa glycoprotein can be seen in 
Figure 3.3C lane 11, blue arrow. The gel was loaded with mucin samples to which 
albumin was added. A clear separation by molecular weight between the 40-50 kDa 
glycoprotein and albumin was demonstrated by staining the gel with Ponceau S, for 
albumin (Figure 3.3C lanes 1-12, black arrow), and followed with PAS for the 
glycoprotein (Figure 3.3C lanes 1-12, blue arrow). From this we were able to confirm 
that the piece removed from the gel (Figure 3.3D, blue arrow) was indeed the PAS 


























     
                                                                       
       
 
 
Figure 3.3 Analysis by SDS-PAGE of purified mucin obtained from specimens resected for 
gastric cancer. Freeze-dried mucin (400-500 µg) from patients with various gastric cancers was 
prepared in reducing sample application buffer and separated on 10% SDS-PAGE. (A) Gel stained with 
PAS showing the 40-50 kDa glycoprotein (circled). (B) Ponceau S with black arrow showing the 
“blob” of albumin.  Lanes are numbered on the top of each gel. Gels (A) and (B) contain samples in the 
following order: Lane 1 (200 µg BSA), lane 2 (M, 55yr, partial gastrectomy, iac), lane 3 (M, 53yr, 
partial gastrectomy, iac), lane 4 (F, 74yr, partial gastrectomy, dac), lane 5 (M, 60yr, partial 
gastrectomy, srac), lane 6 (F, 57yr, total gastrectomy, dac), lane 7 (M, 60yr, partial gastrectomy, dac). 
(C) Gel double stained with Ponceau S and PAS. Lanes 1-6 (M, 55yr, partial gastrectomy, iac) and 
lanes 8-11 (F, 74yr, partial gastrectomy, dac) were spiked with BSA. Lanes 7 and 12 contained BSA 
only. (D) Eppendorf containing the 40-50 kDa glycoprotein cut from the gel (C) in the region indicated 
by the blue arrow, below albumin (black arrow) The cut gel was stored at -20°C until immunization.  
(Abbreviations: M – male, F – female, iac – intestinal type carcinoma, dac – diffuse carcinoma, srac – 



































3.2.4 Production of polyclonal anti-(40-50 kDa glycoprotein) antibody  
 
Here we describe the production of a polyclonal antibody to the 40-50 kDa 
glycoprotein using an efficient immunization method described by Bellstedt et al. 
(1987). A three month old female rabbit was immunized intravenously with the 40-50 
kDa glycoprotein (Figure 3.4), complexed to acid-treated Salmonella minnesota R595 
bacteria. When the optimal antibody production was achieved using this method, 24 
ml of blood was drawn from the central ear artery with a syringe and allowed to clot. 
The antiserum was separated from the blood clot by centrifugation and stored at -










Figure 3.4. Immunisation with the 40-50 kDa glycoprotein. The 40-50 kDa glycoprotein excised 
from the gels (in sufficient quantities) was stored in Eppendorf tubes at -20°C until immunization. 
Upon immunization, the 40-50 kDa glycoprotein complexed to acid-treated Salmonella minnesota 
R595 bacteria (ratio by dry mass of protein to bacteria was 1 to 5) was intravenously introduced into a 
three month old female rabbit. Blood (2.0 ml) was drawn from the central ear artery using a syringe 
prior to immunization as a negative control. Boosts consisting of 3 immunizations within a week, of the 
same amount of protein- naked bacteria complex, were administered intravenously in order to collect 
more serum. When the optimal antibody production was achieved, 24.0 ml of blood was drawn and the 


















3.2.5 Dot blot analysis  
 
Samples where prepared in SDS sample application buffer and applied directly onto a 
nitrocellulose membrane. Membranes were then vacuum blotted at a pressure of 40-
50 bars for 1 h and probed with the anti-(40-50 kDa glycoprotein) antibody followed 
by the secondary goat anti-rabbit HRP antibody. Detection was carried out using an 
ECL kit. Cross reactivity of the antibody with albumin (BSA) and mucin from various 
sources (PMP, PGC, FAP and CGC) was observed. 
 
     
 
Figure 3.5. Dot blot showing antibody cross-reactivity. Samples purified by two spins of CsCl 
density ultracentrifugation were freeze-dried, dissolved in reducing SDS loading buffer and then boiled 
for 1 min. Crude samples suspended in 6M GuHCl containing protease inhibitors were centrifuged at 
105 000 x g for 1 h at 4°C to remove insoluble debris. The supernatant containing mucin was mixed 
with SDS loading buffer at ratio 1 to 1 (v/v) and then boiled for 1 min. Samples were then vacuum 
blotted onto nitrocellulose membrane at a suction pressure of 40–50 bars for 1 h. The rabbit antiserum 
raised against the 40-50 kDa glycoprotein was used as the primary antibody without the addition of 
HSA followed by secondary goat anti-rabbit HRP antibody. ECL was carried out for the detection of 
antibody immunoreactivity. 
(Abbreciations: PGC - purified gastric cancer, PMP - pseudomyxoma peritonei, BSA - bovine serum 




























3.2.6 Western blot analysis   
 
Western blotting is a method used to detect a specific protein in a given sample. 
Mucin samples were electrophoresed on a 1-D SDS-PAGE and transferred onto 
nitrocellulose membranes. Membranes were probed with the polyclonal antibody at   
1 : 5000 dilution diluted only with TBS (without HSA) (Figure 3.6A) and with TBS 
(with HSA) (Figure 3.6B). After washing with TBST (3 x 5 min) membranes were 
incubated with goat anti-rabbit secondary antibody. Detection was by an ECL kit. 
 
Some cross reactivity of the antibody with albumin was seen when the antibody to the 
40-50kDa glycoprotein was prepared without HSA (added to the antibody dilution) 
(Figure 3.6A, lanes: 1-5 and 7-8). The strongest binding to our glycoprotein of interest 
can be seen in lane 6 (black arrow) which was a sample purified from a gastric cancer 
specimen. When the antibody to the 40-50 kDa glycoprotein was diluted in a buffer 
containing HSA, reactivity was observed with cancer mucin (Figure 3.6B, blue arrow) 
presenting as a smear at the top of the running gel and with specificity to the 40-50 
kDa glycoprotein (Figure 3.6B, lanes 6 and 9, green arrow). In the lanes which were 
positive for the 40-50 kDa glycoprotein (Figure 3.6B, lanes 6 and 9), no reactivity 
was noted in the region of albumin at 66-70 kDa (red arrow). Very faint material was 
seen below the Mr ~ 40-50 kDa band. The immunologically active fragments showing 
material above 67 kDa might suggest the existence of non-specific binding of this 
























   
 A                                                                     B 
Figure 3.6. Western blot of the 40-50 kDa glycoprotein. Following two CsCl density gradient steps, 
purified mucins (300-500 ug) and BSA (190-200 ug) were electrophoresed on SDS-PAGE gel (3% 
stacking gel and 10% running gel). After electrophoresis, proteins were transferred onto a 
nitrocellulose membrane using a semi-dry electroblotting unit for 1h. Membranes were probed using 
the antibody to the 40-50 kDa glycoprotein. Immunoreactivity was detected using an ECL kit and films 
were processed using a standard X-ray developer. (A) Primary antibody prepared without human serum 
albumin (HSA) and showing high cross reactivity. Lane 1 (crude PMP), lane 2 (crude PCC), lane 3 
(crude PMP), lane 4 (purified FAP), lane 5 (CGC), lane 6 (PGC), lanes 7 and 8 (BSA). 
(B) Primary anti-(40-50 kDa glycoprotein) antibody incubated with HSA showing no cross-reactivity. 
Lane 1 (BSA), lane 2 (PCC), lane 3 (CGC), lane 4 (PGC), lane 5 (crude gastric cancer), lane 6 (PGC), 
lane 7 (purified PMP), lane 8 (purified FAP), lane 9 (PGC) and lane 10 (BSA).  
(Abbreviations: PMP - pseudomyxoma peritonei, PCC - purified colon cancer, FAP - familial 
adenomatous polyposis coli, CGC - crude gastric cancer, PGC - purified gastric cancer and BSA - 




Crude mucus, scraped from the gastrectomy specimen of patients with cancer, was 
diluted at a 1 : 5 ratio with ice cold buffer containing 6 M guanidinium chloride 
(GuHCl) and proteolytic inhibitors (PI) as a precaution against endogenous 
proteolysis during the preparation of crude mucus from all gastrectomy specimens 
(Mall, 1988). The use of denaturing solvents (GuHCl) and proteinase inhibitors to 
extract mucins has been shown to inhibit degradative enzymes during the extraction 
and purification of mucins (Carlstedt and Sheehan, 1982). The purification of gastric 
mucin by CsCl density gradient ultracentrifugation has been reported to be a method 
of choice and is widely used in mucin research to yield pure mucin (Pearson et al., 
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1980; Creeth and Denborough, 1970). The samples had very little detectable levels of 
the protein after the second spin in CsCl. 
 
Even in purified preparations, the 40-50 kDa PAS positive fragment was always 
associated with albumin on SDS-PAGE (Mall et al., 1990, 1992, 1999). This 
glycoprotein reproducibly appeared as a smear of PAS positive material on gels, both 
in this study and that of Mall et al. (1999), in which mucins were purified from crude 
mucus scrapings. This is another indication of the extent of glycosylation of this 
fragment that would also have contributed to it fractionating with mucins in a CsCl 
gradient. A better separation of albumin and the 40-50 kDa glycoprotein than that 
reported by Mall et al. (1999) (who used the 10% acrylamide gels) was obtained on 
12% SDS-PAGE in this study (Figure 3.2B). Mucins from the cancer patients were 
heterogeneous when analyzed on SDS-PAGE stained with PAS (Figure 3.2A), with 
some samples showing the PAS positive 40-50 kDa glycoprotein, and others not. 
Despite equivalent amounts of sample applied to the gels, the mucin prepared from 
the cancer specimens had varying amounts of polymer and subunit (Figure 3.2A) and 
the intensity of the 40-50 kDa glycoprotein varied from patient to patient. We cannot 
explain the absence of the glycoprotein in some samples. Mall et al. (1999) reported 
its presence in crude mucus in 8/9 gastric ulcers, 7/7 diffuse carcinomas, 6/7 intestinal 
type carcinoma, 3/3 poorly differentiated carcinoma and 1/1 mixed carcinoma (Mall 
et al., 1999).  
 
Purified mucin from post mortem specimens were taken from the previous study 
(Mall et al., 1999), and used as controls. The 40-50 kDa glycoprotein did not appear 
in the control groups, a finding reported previously by Mall et al. (1999). This study 
has been constrained by a lack of suitable normal tissue due to the new forensic-legal 
regulations governing the use of tissue from cadavers and transplant donors. To 
confirm the presence of the 40-50 kDa glycoprotein in the samples prior to cutting it 
from the gel, gels were electrophoresed in duplicate and one gel stained with PAS 
(Figure 3.3A) to confirm the presence of the 40-50 kDa glycoprotein and the twin gel 
from which the 40-50 kDa glycoprotein was to be cut was stained with Ponceau S 
(Figure 3.3B), a reversible stain recommended for staining proteins required for 
immunization purposes. The 40-50 kDa glycoprotein was cut from the gel stained 











antigenic and binds to the glycoprotein non-reversibly (D. U. Bellstedt, personal 
communication). In both gels, BSA was loaded in lane 1 and stained positively with 
Ponceau S (Figure 3.3B) and not with PAS (Figure 3.3A). This was another 
confirmation that this glycoprotein was not an artifact of albumin but a separate 
glycoprotein closely associated with albumin on SDS-PAGE, with albumin being 
associated with it even after purification (Mall et al., 1999).  
 
We could now safely assume that the 40-50 kDa glycoprotein was just below the 
albumin blob as an unstained protein on the Ponceau S stained gel (Figure 3.3B). We 
therefore cut the gel in this region and stored the pieces in Eppendorf tubes at -20ºC 
until further use. To confirm that the piece of removed gel (Figure 3.3B) was indeed 
the PAS positive glycoprotein, we prepared purified mucin samples and added 
albumin to them. After electrophoresis, the gel was stained firstly with Ponceau S 
followed by PAS (Figure 3.3C). This result showed the clear regional separation 
between the PAS positive 40-50 kDa glycoprotein and the Ponceau S positive 
albumin band. Although single staining was used to analyze the 40-50 kDa 
glycoprotein, double staining (Figure 3C) was used for documentation purposes only 
and the material on this gel was not used for immunological experiments. However, 
this result confirmed the close association pattern between the 40-50kDa glycoprotein 
and albumin, reported previously by Mall et al. (1999). Although stomachs of patients 
with gastric cancer are known to produce excessive amounts of albumin, these 
findings continued to intrigue us as they did previously (Mall et al., 1999) because of 
the failure to remove albumin from the sample preparations even after 2 and 
sometimes 3 CsCl/GuHCl spins (Mall – personal communication).   
 
Prior to immunization, the 40-50 kDa glycoprotein stored in Eppendorf tubes was 
electro-eluted from the SDS-PAGE cut piece of gel and coupled to phenol treated 
bacteria in a ratio 1 : 5.  The method, described by Bellstedt et al. (1987), was our 
preferred method as it allows for antibodies to be raised where the antigens retrieved 
from studies are only available in very small amounts. Indeed in our study, samples 
were obtained with difficulty with approximately 30 resections from 2006 to 2008. 
Our study was reliant on the scheduling of gastric cancer surgery for the collection of 
mucus specimens with less than a milligram of purified mucin obtained from each 











antibodies using conventional methods. Another important consideration is that we 
analysed each sample individually and did not pool the mucin samples. Dot blot 
assays where performed as a quick check for antibody cross reactivity against albumin 
(BSA). Faintly stained (BSA, PMP) as well as heavily stained (CGC, FAP, PGC) 
patches can be seen in Figure 3.5. This prompted us to do a more thorough 
investigation using Western blotting methods. The specificity of the antibody to the 
40-50 kDa glycoprotein was determined by Western blotting. In the first experiment, 
the anti-(40-50 kDa glycoprotein) antibody was tested for reactivity against mucin 
from various sources which included crude PMP, PCC and purified FAP. It was also 
tested against BSA and against crude and purified gastric cancer mucin. It was seen 
that the anti-(40-50 kDa glycoprotein) antibody in Figure 3.6A also reacted with 
albumin, shown as bands around the region 66-70 kDa where albumin is usually 
found. This indicated that the 40-50 kDa glycoprotein was possibly contaminated with 
some albumin upon its retrieval from the gel.  
 
In order to confirm whether the cross-reactivity presented by the 40-50 kDa antibody 
was associated with albumin contamination, we incubated the anti-(40-50 kDa 
glycoprotein) antibody with HSA for 1 h to block any antibody that might recognize 
albumin. The effect of treating the anti-(40-50 kDa glycoprotein) with HSA 
eliminated cross reactivity (Figure 3.6B). This result demonstrated that the cross 
reactivity observed in Figure 3.6A was indeed due to the presence of albumin as a 
contaminant or as a product complexed to the 40-50 kDa glycoprotein. In Figure 
3.6B, the anti-(40-50 kDa glycoprotein) showed reactivity with cancer mucin. This 
could mean that some 40-50 kDa glycoprotein could be non-specifically bound with 
mucin. This explanation is likely considering this 40-50 kDa fragment actually 
fractionated with mucin in a CsCl gradient. In the study by Mall et al. (1999) this 
fragment was detectable on a Western blot using M1 monoclonal antibodies (1-13M1, 
2-12M1, 9-13M1 and 58M1) at a similar molecular weight and range to the 
glycoprotein of interest. M1 antibodies are known to react with degraded fragments of 
MUC5AC (Bara et al., 1998). However, bands were also positive for larger fragments 
suggesting non-specific binding with larger mucins (Mall et al., 1999). However, we 
were successful in raising the polyclonal antibody to our 40-50 kDa glycoprotein, 
setting the stage for determining by immunohistochemistry, its localization and 













IMMUNOHISTOCHEMICAL ANALYSIS OF THE 40-50 kDa 




Here we describe, using immunohistochemical techniques, the expression and 
location, in gastric tissue, of the 40-50 kDa glycoprotein using the polyclonal 
antibody raised against it as described in Chapter 3. Serial sections (2 µm) were cut 
from paraffin wax embedded tissue blocks and stained with haematoxylin and eosin 
(H&E) for diagnosis, periodic acid-Schiff (pH 2.5)/Alcian blue (PAS/AB) to identify 
neutral mucins and sialomucins and with high iron diamine/Alcian blue (HID/AB), to 
identify sulfomucins and sialomucins. The tissue distribution of the 40-50 kDa 
glycoprotein was investigated by immunohistochemistry using the anti-(40-50 kDa 
glycoprotein) antibody (we developed and described in Chapter 3). The expression of 
this glycoprotein was investigated in normal, intestinal metaplasia and gastric 
carcinoma tissue sections prepared from the same patients (Table 1) from whom the 
mucus gel was scraped for the isolation and purification of the 40-50 kDa 
glycoprotein. We also looked at the expression of mucin using anti-(MUC1, 
MUC1core, MUC2, MUC4, MUC5AC and MUC6) antibodies (Table 2) to be able to 
compare those with the expression of the 40-50 kDa glycoprotein. We evaluated the 
slides quantitatively by looking at 100 cells at ×400 magnification. The degree of 
positive staining for the 40-50 kDa glycoprotein and mucins was evaluated as follows: 
1+ (5-25%) few positive cells; 2+ (26-50%) well defined areas with positive cells, 3+ 
(51-75%) extensive areas with positive cells and 4+ (>75%) most cells stained. 
 
4.2 Results:  
 
4.2.1 Normal stomach 
 
The normal gastric mucosa expressed neutral mucins (PAS) in the surface epithelium 
and in the deep mucus glands with no HID/AB staining. The following results are 











consistently expressed in the cytoplasm of parietal cells (20/20) as follows: 2 cases 
1+; 2 cases 3+ and 16 cases 4+ (Figure 4.1A). None of the mucin antibodies used in 
this study stained parietal cells. MUC1 was consistently expressed in the surface 
epithelium in the mucus neck cells and in the deep gastric mucus glands (26/26) 
(Figure 4.1B) with all cases showing 4+. There was inconsistent staining of MUC4 in 
the surface epithelium (10/26) in 16 cases <5%; 3 cases 1+; 5 cases 2+ and 2 cases 4+ 
and in the deep mucus glands (5/26) in 21 cases <5%; 3 cases 1+ and  2 cases 4+. 
MUC5AC consistently stained the surface epithelium (26/26) with 2 cases 3+ and 24 
cases 4+ (Figure 4.1C). MUC6 was consistently expressed in the deep mucus glands 
(25/25) with 3 cases 2+; 3 cases 3+ and 19 cases 4+ (Figure 4.1D).  MUC1 core and 
MUC2 were not expressed in the normal gastric mucosa. 
 
The cytoplasmic expression of the 40-50 kDa glycoprotein in parietal cells of normal 
mucosa is shown at higher magnification in Figure 4.2. In comparison, human serum 
albumin (HSA) (Figure 4.2 B) MUC5AC (Figure 4.2C) and MUC6 (Figure 4.2D) 
were not expressed in parietal cells. The area of the stomach that did not contain 
parietal cells, such as the antrum, showed no staining with the 40-50 kDa 
glycoprotein. These cases (n=9) were excluded in tissue sections probed with the anti-
(40-50 kDa glycoprotein) antibody. One slide with tissue sections probed for MUC6 
repeatedly washed off the slide during antigen retrieval in the pressure cooker and 
therefore could not be evaluated. All mucin antibodies showed good staining in 
control tissues. A graphical comparison for the immunohistochemical results of the 





















     
                                
 
Figure 4.1 Expression pattern of the 40-50 kDa glycoprotein, MUC1, MUC5AC and MUC6 in the 
normal gastric mucosa. (A) The 40-50 kDa glycoprotein was highly expressed only in parietal cells. 
(B) MUC1 was expressed in both the surface epithelium and in the deep mucus glands. (C) MUC5AC 
was consistently expressed in the surface epithelium and mucus neck cells. (D) MUC6 was expressed 

















     
 
     
 
Figure 4.2 Immunodetection of the 40-50 kDa glycoprotein in the parietal cells of normal gastric 
mucosa. (A) Extensive staining of parietal cells shown by the red arrows, was consistently seen on 
tissue sections (normal adjacent to and away from tumour) stained with the anti-(40-50 kDa 
glycoprotein) antibody. This was also observed in the control tissues sampled away from cancer. (B) 
Albumin was expressed only in chief cells and not in parietal cells shown by the blue arrows. (C) 
MUC5AC was expressed in the mucus cells in the neck region and not in parietal cells shown by the 
black arrow. (D) MUC6 was expressed in the deep mucus glands and not in parietal cells shown by the 
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Figure 4.3 Expression of the 40-50 kDa glycoprotein and mucin in normal gastric mucosa. The 
40-50 kDa glycoprotein was consistently expressed only in parietal cells, MUC1 consistently in both 
the surface mucus cells and the deep mucus glands, MUC4 in few surface mucus cells and the deep 
mucus glands, MUC5AC consistently in the surface mucus cells and MUC6 consistently in the deep 




Table 4.1 Immunohistochemical expression of the 40-50 kDa glycoprotein and 
mucins in normal stomach tissue 
 
 
Antigen Superficial mucus cells 
(n=26) 
Deep mucus glands (n=26) Parietal cell (n=20) 
40-50 kDa 
glycoprotein  
0 0 20 (100%) 
MUC1 26 (100%) 26 (100%) 0 
MUC1 core 0 0 0 
MUC2 0 0 0 
MUC4 10 (39%) 5 (19%) 0 
MUC5AC 26 (100%) 0 0 
MUC6 0 25 (100%)* 0 




(patients = 20) 
Deep mucus glands 
(patients = 26)
Surface mucus cells 
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Table 4.2 Degree of staining of the 40-50 kDa glycoprotein and mucin in normal 
gastric mucosa 
 
Antigen No. of 
cases 
0(<5%) 1+ (5-25%) 2+ (26-50%) 3+ (51-75%) 4+ (>75%) 
40-50 kDa glycoprotein 20 20 0 0 0 0
MUC1 26 0 0 0 0 26 
MUC1core 26 26 0 0 0 0
MUC2 26 26 0 0 0 0
MUC4 26 16 3 5 0 2 
MUC5AC 26 0 0 0 2 24 
MUC6 26 26 0 0 0 0
A. Superficial epithelium  
 
Antigen No. of 
cases 
0(<5%) 1+ (5-25%)  2+ (26-50%) 3+ (51-75%) 4+ (>75%) 
40-50 kDa glycoprotein 20 20 0 0 0 0
MUC1 26 0 0 0 0 26 
MUC1core 26 26 0 0 0 0
MUC2 26 26 0 0 0 0
MUC4 26 21 3 0 0 2 
MUC5AC 26 26 0 0 0 0 
MUC6 25* 0 0 2 4 19 
B. Deep mucus glands 
 
Antigen No. of 
cases 
0(<5%) 1+ (5-25%)  2+ (26-50%) 3+ (51-75%) 4+ (>75%) 
40-50 kDa glycoprotein 20 0 2 0 2 16 
MUC1 26 26 0 0 0 0
MUC1core 26 26 0 0 0 0
MUC2 26 26 0 0 0 0
MUC4 26 26 0 0 0 0
MUC5AC 26 26 0 0 0 0
MUC6 26 26 0 0 0 0













4.2.2 Intestinal metaplasia 
 
Intestinal metaplasia (IM) was classified according to Filipe. (1992). Mucin 
histochemistry was used to identify specific subtypes of IM based on the pattern of 
cell differentiation and mucin expression. Neutral mucins were decreased in intestinal 
metaplasia compared to normal gastric mucosa. An intense blue staining of 
sialomucins was observed in the complete IM (Figure 4.4A), whereas sialomucins and 
sulfomucins were expressed in the incomplete IM (Figure 4.4B).  
 
The following results are summarised in Table 4.3 and Table 4.4. The 40-50 kDa 
glycoprotein was consistently expressed in the columnar cells in complete (type I) IM 
(12/12) (Figure 4.4C) in 6 cases 1+; 2 cases 2+ and 4 cases 3+, in the incomplete 
(type II) IM (5/5) (Figure 4.4D) in 3 cases 1+; 1 case 3+ and 1 case 4+ and in one case 
of the incomplete (type III) (1/1) as 4+.  
 
The following immunohistochemical results for the expression of mucins are 
summarised in Table 4.3. Mucin expression in the complete (type I) IM was as 
follows: MUC1core (1/12), MUC2 (7/12) and MUC5AC (3/12). MUC1, MUC4 and 
MUC6 were not expressed in the complete (type I) IM. In the incomplete (type II) IM, 
mucins were expressed as follows: MUC1 core (1/5), MUC2 (2/5), MUC5AC (1/5) 
and MUC6 (2/5). MUC1 and MUC4 were not expressed in the incomplete IM. MUC2 
was frequently expressed in the complete (type I) (Figure 4.4E) whereas in the 
incomplete (type II) IM, both MUC2 (Figure 4.4E) and MUC6 were expressed more 
frequently when compared to other mucins. MUC5AC (1/1) was the only mucin 
expressed in the incomplete (type III) IM.  
 
In the normal small intestine (used as a positive control) the 40-50 kDa glycoprotein 
was consistently expressed in the cytoplasm of absorptive columnar cells (Figure 4.5). 
A graphical comparison of immunohistochemical results of the expression of the 40-














                 
                
 
               
 
 
Figure 4.4. Histochemical (HID/AB) and immunohistochemical localization of the 40-50 kDa 
glycoprotein and MUC2 in intestinal metaplasia of the stomach. (A) HID/AB showing sialomucins 
in goblet cells of complete IM and (B) shows sialomucins and sulfomucins in goblet and columnar 
cells in incomplete IM (x40). The 40-50 kDa glycoprotein was expressed in the cytoplasm of columnar 
cells in complete (C) and incomplete (D) IM but not in the goblet cells (x40). MUC2, a typical 
intestinal mucin, was expressed in the supranuclear area of the goblet cells of both complete (E) and 


















Figure 4.5. The 40-50 kDa glycoprotein expressed in columnar cells of the normal small intestine. 
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Figure 4.6 Expression of the 40-50 kDa glycoprotein and mucin in intestinal metaplasia of the 
stomach. The 40-50 kDa glycoprotein was consistently expressed in all types of IM, MUC1core in a 
few cases of complete (types I) IM and incomplete (type II) IM, MUC2 more in complete (type I) IM 
than incomplete (type II) IM, MUC5AC in a few cases of complete (types I) IM and incomplete (type 
II) IM and in 1 case of the incomplete (type III) IM, and MUC6 only in incomplete (type II) IM. 
 
 
Table 4.3 Immunohistochemical expression of the 40-50 kDa glycoprotein and 
mucin in intestinal metaplasia of the stomach 
 
 
Antigen Complete (Type I) 
IM [n = 12] 
Incomplete (Type II) 
IM [n = 5] 
Incomplete (Type III) 
IM [n = 1] 
40-50kDa glycoprotein  12 (100%) 5 (100%) 1 (100%) 
MUC1 0 0 0 
MUC1 core 1 (8%) 1 (20%) 0 
MUC2 7 (58%) 2 (40%) 0 
MUC4 0 0 0 
MUC5AC 3 (25%) 1 (20%) 1 (100%) 
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Table 4.4 Degree of staining of the 40-50 kDa glycoprotein in intestinal 
metaplasia of the stomach 
 
Metaplasia No. of 
cases 
0(<5%) 1+ (5-25%) 2+ (26-50%) 3+ (51-75%) 4+ (>75%) 
Complete (type I) 12 0 6 2 4 0 
Incomplete (type II) 5 0 3 0 1 1 
Incomplete (type III) 1 0 0 0 0 1 
 
 
4.2.3 Gastric cancer 
 
We studied 13 cases of intestinal type, 7 diffuse, 1 mixed (intestinal and diffuse), 4 
signet-ring cell and 2 mucinous type carcinomas. The well differentiated glands of the 
intestinal type carcinoma showed cytoplasmic staining for the 40-50 kDa glycoprotein 
(Figure 4.7A) and showed a similar expression in the diffuse type cancers (Figure 
4.7B). The 40-50 kDa glycoprotein was also expressed in the cytoplasm of signet-ring 
cell (Figure 4.8A) and mucinous carcinomas (Figure 4.8B). 
 
The following results are summarised in Table 4.5 and Table 4.6. The 40-50 kDa 
glycoprotein was consistently expressed in the intestinal type carcinoma (13/13) with 
the degree of staining as follows: 4 cases 1+; 2 cases 2+; 5 cases 3+ and 2 cases 4+. 
The 40-50 kDa glycoprotein was inconsistently expressed in the diffuse carcinoma 
(4/7) with 3 cases <5%; 3 cases 2+ and 1 case 3+. In the mixed (intestinal and diffuse) 
carcinoma (1/1), the 40-50 kDa glycoprotein was expressed in both components as 
3+. In the signet-ring cell carcinomas, the 40-50 kDa glycoprotein showed 
inconsistency (2/4) with 2 cases <5%; 1 case 1+ and the other case 2+. The 40-50 kDa 
glycoprotein was expressed in both cases of mucinous carcinomas (2/2): 1 case 1+ 
and the second case 2+.   
 
MUC1 was consistently expressed in the intestinal type carcinoma (12/13) with the 
degree of staining as follows: 1 case < 5%; 3 cases 1+; 1 case 2+; 5 cases 3+ and 3 
cases 4+. In the diffuse type carcinoma, MUC1 was consistently expressed (7/7) with 











the mixed (1/1) (intestinal and diffuse) carcinoma as 2+. In the signet-ring cell 
carcinomas, MUC1 showed consistency (4/4) with 2 cases 1+; 1 case 2+ and 1 case 
3+. MUC1 was expressed in the mucinous carcinomas with 1 case 2+ and the other 
case 3+. 
 
In the intestinal type carcinomas (10/13), MUC1 core was expressed with the degree 
of staining as follows: 3 cases < 5%; 4 cases 1+; 1 case 2+; 4 cases 3+ and 1 case 4+. 
In the diffuse carcinomas (1/7) as follows: 6 cases <5% and 1 case 2+. In the mixed 
(intestinal and diffuse) carcinoma (1/1), MUC1 core was expressed in both 
components of carcinoma as 2+. In the signet-ring cell carcinomas, MUC1 core was 
expressed (2/4) in 2 cases <5%; 1 case 2+ and the other case 4+. MUC1 core was 
expressed in both cases of mucinous carcinomas (2/2): 1 case 2+ and the second case 
3+.   
 
MUC2 was inconsistently expressed in the intestinal type carcinoma (2/13) with the 
degree of staining as follows: 11 cases < 5% and 2 cases 1+. In the diffuse carcinoma 
(2/7), MUC2 was expressed as follows: 5 cases <5%; 1 case 1+ and 1 case 2+. In the 
signet-ring cell carcinomas, MUC2 was expressed (3/4) in 1 case <5%; 1 cases 2+;  1 
case 3+ and 1 case 4+. In mucinous carcinomas, MUC2 was expressed (1/2) as 
follows: 1 case <5% and 1 case 3+.  MUC2 was not expressed in the mixed (intestinal 
and diffuse) carcinoma (0/1). 
 
MUC4 was expressed in the intestinal type carcinoma (8/13) with the degree of 
staining as follows: 5 cases < 5%; 4 cases 1+; 3 cases 2+ and 1 case 3+. In the diffuse 
carcinoma (2/7), MUC4 was expressed as follows: 5 cases <5% and 2 cases 2+. 
MUC4 was expressed in both components of the mixed (1/1) intestinal and diffuse 
carcinoma as 2+. MUC4 was not expressed in the signet-ring cell carcinomas and 
mucinous carcinomas. 
 
MUC5AC was expressed in the intestinal type carcinoma (6/13) with the degree of 
staining as follows: 7 cases <5%; 3 cases 1+; 2 cases 2+ and 1 case 3+. In the diffuse 
carcinoma (3/7), MUC5AC was expressed as follows: 4 cases <5%, 2 cases 2+ and 1 











follows: 1 case <5%; 2 cases 3+ and 1 case 4+. MUC5AC was not expressed in the 
mixed (intestinal and diffuse) carcinoma and in the mucinous carcinomas. 
 
MUC6 was expressed in the intestinal type carcinoma (4/13) with the degree of 
staining as follows: 9 cases <5%; 3 cases 1+ and 1 case 3+. In the diffuse carcinoma 
(1/7), MUC6 was expressed as follows: 6 cases <5% and 1 case 1+. In the signet-ring 
cell carcinomas, MUC6 was expressed (1/4) in: 3 cases <5% and 1 case 1+. MUC6 
was not expressed in the mixed (intestinal and diffuse) carcinoma and in the mucinous 
carcinomas. A summary of the heterogeneous expression of the 40-50 kDa 






























Figure 4.7 The 40-50 kDa glycoprotein expressed in the cytoplasm of intestinal and diffuse type 
gastric carcinomas. The 40-50 kDa glycoprotein was expressed in the cytoplasm of neoplastic glands 
in the intestinal type carcinoma (A) (x40) and by cancer cells of the diffuse type (B) shown invading 





















Figure 4.8 The 40-50 kDa glycoprotein expressed in the cytoplasm of signet-ring cell and 
mucinous carcinomas. (A) The 40-50 kDa glycoprotein was expressed in the cytoplasm of infiltrative 
signet-ring cells (x20). (B) In mucinous carcinomas, the 40-50 kDa glycoprotein was expressed in 
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Figure 4.9 Summary of the immunohistochemical expression of the 40-50 kDa glycoprotein and 
mucin in human gastric carcinomas. The 40-50 kDa glycoprotein and MUC1 were consistently 
expressed in all carcinomas, more in the intestinal, mixed and mucinous type carcinomas.  MUC1 was 
expressed more in the diffuse and signet-ring cell carcinomas than the 40-50 kDa glycoprotein.  
 
 
Table 4.5 Immunohistochemical expression of the 40-50 kDa glycoprotein and 















13 (100%) 4 (57%) 1 (100%) 2 (50%) 2 (100%) 
MUC1 12 (92%) 7 (100%) 1 (100%) 4 (100%) 2 (100%) 
MUC 1 core 10 (83%) 1 (14%) 1 (100%) 2 (50%) 2 (100%) 
MUC1 12 (92%) 7 (100%) 1 (100%) 4 (100%) 2 (100%) 
MUC 2 2 (15%) 2 (29%) 0 3 (75%) 1 (50%) 
MUC 4 8 (62%) 2 (29%) 1 (100%) 0 0 
MUC 5AC 6 (46%) 3 (43%) 0 3 (75%) 0 





(patients = 13) 
Diffuse type 
(patients = 7) 
Mixed intestinal 
and diffuse 
 (patient = 1) 
Signet-ring cell 
(patients = 4) 
Mucinous 
(patients = 2) 
0     
10    
20    
30    
40    
50
60    
80    
90    
70    



















Table 4.6 Degree of staining of the 40-50 kDa glycoprotein and mucins in gastric 
carcinoma 
 
Antigen No. of 
cases 
0 (<5%) 1+ (5-25%) 2+ (26-50%) 3+ (51-75%) 4+ (>75%) 
40-50 kDa glycoprotein 13 0 4 2 5 2 
MUC1 13 1 3 1 5 3 
MUC1core 13 3 4 1 4 1 
MUC2 13 11 
 
2 0 0 0 
MUC4 13 5 4 3 1 0 
MUC5AC 13 7 3 2 1 0 
MUC6 13 9 3 0 1 0 
A. Intestinal type carcinoma  
 
Antigen No. of 
cases 
0 (<5%) 1+ (5-25%) 2+ (26-50%) 3+ (51-75%) 4+ (>75%) 
40-50 kDa glycoprotein 7 3 0 3 1 0 
MUC1 7 0 0 2 3 2 
MUC1core 7 6 0 1 0 0 
MUC2 7 5 1 1 0 0 
MUC4 7 5 0 2 0 0 
MUC5AC 7 4 0 2 1 0 
MUC6 7 6 1 0 0 0 






















Antigen No. of 
cases 
0 (<5%) 1+ (5-25%) 2+ (26-50%) 3+ (51-75%) 4+ (>75%) 
40-50 kDa glycoprotein 1 0 0 0 Intestinal = 1 
Diffuse = 1 
0
MUC1 1 0 0 Intestinal = 1 
Diffuse = 1 
0 0
MUC1core 1 0 0 Intestinal = 1 
Diffuse = 1 
0 0
MUC2 1 1 0 0 0 0
MUC4 1 0 0 Intestinal = 1 
Diffuse = 1 
0 0
MUC5AC 1 1 0 0 0 0
MUC6 1 1 0 0 0 0
C Mixed (intestinal type and diffuse) carcinoma 
 
Antigen No. of 
cases 
0 (<5%) 1+ (5-25%) 2+ (26-50%) 3+ (51-75%) 4+ (>75%) 
40-50 kDa glycoprotein 4 2 1 1 0 0 
MUC1 4 0 2 1 1 0 
MUC1core 4 2 1 0 0 1 
MUC2 4 1 0 1 1 1 
MUC4 4 4 0 0 0 0 
MUC5AC 4 1 0 0 2 1 
MUC6 4 3 1 0 0 0 
D. Signet-ring cell carcinoma 
 
Antigen No. of 
cases 
0 (<5%) 1+ (5-25%) 2+ (26-50%) 3+ (51-75%) 4+ (>75%) 
40-50 kDa glycoprotein 2 0 1 1 0 0 
MUC1 2 0 0 1 1 0 
MUC1core 2 0 0 1 1 0 
MUC2 2 1 0 0 1 0 
MUC4 2 2 0 0 0 0 
MUC5AC 2 2 0 0 0 0 
MUC6 2 2 0 0 0 0 

















The expression of the 40-50 kDa glycoprotein was determined on 2 µm-thick 
histological sections of human gastric tissue using the anti-(40-50 kDa glycoprotein) 
antibody described in Chapter 3. We examined the expression of the 40-50 kDa 
glycoprotein in normal mucosa adjacent to the tumour site (n=17) and normal mucosa 
cut from uninvolved gastric mucosa (n=3). Immunostaining was regarded as positive, 
if greater than 5% of the cells expressed the antigen (Tables 4.2 and 4.5). The 40-50 
kDa glycoprotein was expressed in the cytoplasm of all parietal cells (Figure 4.2A) 
but not in the surface epithelium and the deep mucus glands of the normal gastric 
mucosa.  
 
When the anti-(40-50 kDa glycoprotein) antibody was prepared without HSA, a 
strong signal of background staining was observed, which we reported as cross 
reactivity in the western blot (see Chapter 3). The reactivity of background material 
due to non-specific binding was inhibited by diluting the anti-(40-50 kDa 
glycoprotein) antibody in HSA. We have used a similar approach here to that in 
western blotting whereby the antibody was incubated with HSA prior to staining and 
thus clear immunostaining was obtained. During optimization of the 40-50 kDa 
antibody, better results were obtained if sections were not subjected to antigen 
retrieval. 
 
Mucin expression is regulated in a cell- and tissue-specific manner (Ho et al., 1993, 
1995). Our results confirmed the cellular and tissue distribution of MUC5AC in the 
surface epithelium as reported by de Bolos et al. (1995) (Figure 4.1B). In keeping 
with previous reports (Reis et al., 1997, 2000; Bartman et al., 1998; Byrd et al., 
1997), we observed MUC6 in the deep mucus glands and mucus cells of the neck 
(Figure 4.1C). One of the negative MUC6 tissue sections repeatedly washed off the 
slide during antigen retrieval in the pressure cooker. A new set of glass slides was 
coated with APES to ensure that the tissue section remained during antigen retrieval. 
However the tissue again washed off the slide after retrieval and therefore could not 
be evaluated. MUC1 was expressed in the mucus cells of the surface epithelium and 
in the glands of the body as reported by Reis et al. (1998) (Figure 4.1D). MUC4 was 











We found no expression of MUC1core and MUC2 in the normal gastric mucosa 
(Figure 4.3). 
 
We could not use cadaver stomachs as normals because these were unfortunately 
unobtainable before 72 h post mortem due to forensic and legal implications. H&E 
staining of sections from these stomachs showed autolysis making them poor controls 
for this study. However, transplant donor stomachs obtained within 30 min of brain 
death were used by Mall et al. (1999) for mucosal scrapings and in which the 40-50 
kDa glycoprotein was shown to be absent. Transplant donor stomachs are now also 
very difficult to obtain because of stringent new ethical regulations.  
 
The surface epithelium of the gastric mucosa is normally lined by columnar cells and 
the presence of goblet cells in the gastric mucosa is an important histological 
parameter that characterizes intestinal metaplasia. In the healthy stomach, surface 
columnar cells produce neutral mucins (Jass et al., 1984). In contrast to the neutral 
mucin produced by the normal columnar cells of the gastric mucosa, goblet cells in 
IM produce sialomucin that are normally secreted by the goblet cells of the small 
intestine, and/or sulphomucin, normally secreted by goblet cells in the large intestine 
(Filipe and Ramachandra, 1995). We found that goblet cells in the complete (type I) 
IM secreted sialomucin (AB) and the columnar cells secreted neutral mucin (PAS). In 
the incomplete (type II) IM, goblet cells secreted sialomucins and occasionally 
sulphomucins (HID/AB) with the columnar cells secreting both neutral and 
sialomucins. In the incomplete (type III) IM, goblet cells secreted sialomucins and/or 
sulphomucins with the columnar cells predominantly secreting sulphomucins. The 
tissue distribution of the 40-50 kDa glycoprotein in normal and intestinal metaplasia 
appears to be different to that of the mucins. In the normal tissue, the 40-50 kDa 
glycoprotein was consistently expressed in parietal cells. In IM, it was consistently 
expressed (18/18) in the columnar cells of all three types of metaplasia (type I, type II 
and type III) looked at in this study. We found varying degrees of staining of the 40-
50 kDa glycoprotein within metaplastic tissue (Table 4.4). The 40-50 kDa 
glycoprotein was mostly present in the cytoplasm of columnar cells (Figure 4.2 C and 
D), additionally showing nuclear reactivity in some cases. The 40-50 kDa 
glycoprotein was weakly reactive (1+) in the majority of the cases, in type I (50%) 











We found MUC2 expression in the goblet cells of complete type I (7/12) and 
incomplete type II IM (2/5). Ho et al. (1995) found MUC2 and MUC3 to be highly 
expressed in IM of the stomach in both goblet and columnar cells. Other studies have 
identified several antigens expressed both in gastric IM and in cancer, but not in 
normal gastric epithelium. These include large-intestine mucin antigen (LIMA) 
(Hertzog et al., 1991), FU-MK-1 (Watanabe et al., 1993) and 91.9H (Ohe et al., 
1994). Several studies raised the possibility that different types of IM may have 
different malignant potential. Jass (1980) and Filipe et al. (1994) associated the 
incomplete type II and III IM with intestinal-type gastric cancer.  
 
We evaluated the expression of the 40-50 kDa glycoprotein and found it to be 
consistently expressed in the different types of gastric carcinomas (intestinal type, 
diffuse, mixed, signet-ring cell and mucinous) we looked at. The well differentiated 
glands of the intestinal carcinoma showed cytoplasmic staining for the 40-50 kDa 
glycoprotein, a similar expression seen in the diffuse type cancers. In the signet-ring 
cell and mucinous carcinomas, the 40-50 kDa glycoprotein was also expressed in the 
cytoplasm. We found that the 40-50 kDa glycoprotein was inconsistently expressed in 
the diffuse and signet-ring cell carcinoma and consistent in the intestinal type (13/13) 
carcinomas.  
 
In the overall comparison, the 40-50 kDa glycoprotein and MUC1 were expressed in 
greater than 80% of the intestinal, mixed and signet-ring cell carcinomas (Table 4.4). 
The 40-50 kDa glycoprotein, MUC1 and MUC1 core were also expressed consistently 
in mucinous carcinomas. Other studies reported that the coexpression of MUC1 and 
MUC5AC increased the metastatic potential of gastric carcinoma cells (Ho et al., 
1995; Taylor et al., 1998). 
 
Overexpression of MUC1 in cancer cells has been reported to decrease cell-cell 
interaction by interfering with the integrin-mediated adhesion (Hilkens et al., 1992; 
Wesseling et al., 1995; Ligtenberg et al., 1992; Makiguchi et al., 1996) thereby 
increasing the metastatic capacity of carcinoma cells and favouring invasion of 
tumour cells  (Hiraga et al., 1998; Utsunomoya et al., 1998). There is enough 
evidence to suggest that tumour cells expressing high levels of MUC1 may have 











cancer-associated MUC1 mucin and synthetic tandem repeats of MUC1 mucin core 
peptide can suppress T cell proliferation and higher levels of MUC1 expression are 
correlated with immuno-suppression in adenocarcinoma patients. In our study, we 
found that gastric carcinomas expressed higher levels of MUC1 than normal gastric 
tissue as has been shown by Lee et al. (2001) (Figure 4.10). Baldus et al. (1998) 
reported that MUC1 was consistently expressed in intestinal type carcinomas than 
signet-ring cell or diffuse carcinomas. We found MUC1 to be consistently expressed 
in the diffuse and signet-ring cell and intestinal types. This combined expression of 
mucin and the 40-50 kDa glycoprotein may alter the biology of the cell, enabling it to 
develop greater potential for malignant transformation and metastases. 
 
The de novo expression of MUC2 in gastric cancer reported by Utsunomiya et al. 
(1998) was confirmed in our study (Figure 4.10), with the exception of the mixed type 
carcinoma. In agreement with previous studies (Reis et al., 2000; Gurbuz et al., 
2002), we observed consistent expression of MUC2 in mucinous carcinomas. MUC2 
expression has been shown to be increased in mucinous carcinomas of the colon, 
breast and ovary (Hanski et al., 1997). These researchers reported higher MUC2 
expression in signet-ring cell carcinomas. Also, this study showed that MUC5AC and 
MUC6 expression decreased during gastric carcinogenesis (Figure 4.10), a feature 
reported by Pinto-de-Sousa et al. (2002). High levels of gastric mucins and relatively 
low levels of intestinal mucins have been reported in diffuse tumour cells (Lopez-
Ferrer., 2000). MUC5AC has been shown to mostly associate with diffuse and signet-
ring cell carcinomas (Reis et al., 1997; Pinto-de-Sousa et al., 2002). We found 
MUC5AC to be expressed more in the signet-ring cell carcinomas and less in the 
diffuse carcinomas. The absence MUC5AC in mucinous carcinomas of the colon has 
been suggested to be a prognostic factor for more aggressive colorectal carcinomas 
(Jass and Roberton, 1994). The absence of MUC5AC expression in mucinous 
carcinomas was confirmed in our study (Figure 4.10). However, Kocer et al. (2004) 
reported that in gastric cancer, MUC5AC positive tumours have worse prognoses than 
MUC5AC negative tumours.  
 
In summary and based on the hypothesis that this glycoprotein might play a role in 
gastric carcinogenesis, we investigated by immunohistochemistry its expression in 











mucosa, the 40-50 kDa glycoprotein was expressed in parietal cells and not in the 
mucus producing cells. This pattern of expression was evident in both the uninvolved 
mucosa (n=3) and the mucosa next to the tumour site (n=17). The expression of the 
40-50 kDa glycoprotein in parietal cells of normal gastric tissue adjacent to the 
tumour raises interesting questions. Akyurek et al. (2002) reported finding MUC1 in 
the canalicular system of parietal cells. We cannot say for sure that the observed 
extensive parietal cell staining with the anti-(40-50 kDa glycoprotein) is only in the 
transitional gastric mucosa as we were unable to obtain normal stomachs to include in 
this study. This 40-50 kDa glycoprotein may be an important factor in the 
pathogenesis of gastric cancer. Despite the assumed importance of the 40-50 kDa 
glycoprotein, there is still limited biochemical understanding of its association with 
gastric mucins, its identity and how this is altered during gastric disease.  
 
We were unable to evaluate our findings statistically because of the small number of 
samples available to us for this study. Also, the location of the 40-50 kDa 
glycoprotein and its pattern of expression differed in the different groups, namely 
normals, intestinal metaplasia and cancer. In the next chapter (Chapter 5), we report 
how we used proteomics to perform a more complete analysis of the 40-50 kDa 
glycoprotein and by using two-dimensional polyacrylamide gel electrophoresis (2-D 
PAGE) in combination with MALDI-TOF MS to define the protein components of 
































PROTEOMIC ANALYSIS AND IDENTIFICATION OF THE 40-50 kDa 




The purpose of the study reported in this chapter was to analyze the 40-50 kDa 
glycoprotein (resolved as a single band via SDS-PAGE in Chapter 3) using 2-
dimensional polyacrylamide gel electrophoresis (2-D PAGE), in order to produce a 
peptide sequence that would help identify it by using the Matrix-assisted laser 
desorption ionization/time-of-flight mass spectrometry (MALDI-TOF MS). Two-
dimensional gel electrophoresis (2-D PAGE), mass spectrometry (MS) and 
bioinformatics are the key components of current proteomics technology (Shevchenko 
et al., 2002; Giorgianni et al., 2003). 2-D PAGE is a principal tool in proteomics that 
separates proteins according to their isoelectric point (pI) by isoelectric focusing (IEF) 
in the first dimension and according to their molecular weight (Mr) by SDS-PAGE in 
the second dimension. The principle behind MALDI-TOF MS is that the masses of 
the tryptic digested peptide fragments are measured and fragmentation of the peptide 
is generated by collisionally activated dissociation. Then the proteins can be identified 
because the sequence of the unknown peptide can be determined from the resulting 
fragmentation patterns using bioinformatic programs. 
 
In the previous chapter (Chapter 4), we showed that the tissue localization of the 40-
50 kDa glycoprotein was different from that of mucin, in that it was secreted by 
parietal cells in the normal gastric tissue. This raised the question of whether it was a 
mucin at all, and we hoped that the answer would be provided by the technique of 
proteomics. We isolated the glycoprotein from the crude mucus and separated it from 
purified mucin in patients with gastric carcinoma. We used 2-D PAGE for the 
analysis of the 40-50 kDa glycoprotein. We separated the 40-50 kDa glycoprotein 
using the first dimensional IEF technique, that separates proteins according to their pI, 












We rehydrated strips (pH 3-10, BIO-RAD) with purified, freeze-dried gastric cancer 
mucin (100-200 µg) solubilized in urea buffer (9 M Urea, 2 M Thiourea and 4% (w/v) 
CHAPS). The IPG strips were overlaid with mineral oil and allowed to rehydrate 
overnight at room temperature. After IEF, proteins were electrophoresed on SDS-
PAGE (12%, w/v) and stained with Coomassie Brilliant Blue or Periodic Acid Schiff 
(PAS). These separation parameters allowed for the resolution of proteins differing by 
a single charge, thereby allowing in vivo modifications such as post-translational 
modifications to be detected. Gels were scanned using a Canon scanner (CanoScan 




5.2.1 Two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) 
 
The 40-50 kDa glycoprotein profile was better resolved on 7 cm strips (pH 3-10). 
Well resolved 2-D PAGE with clear separation of the 40-50 kDa spots was achieved 
by loading the optimized amount of mucin sample (100 µg mucin for gels stained 
with Coomassie Blue and 200 µg mucin for gels stained with PAS). Characterization 
of the 40-50 kDa glycoprotein in 2-D PAGE revealed three spots of varying 
abundance after Coomassie Brilliant Blue staining (Figure 5.1A, arrows 1-3) and one 
spot after staining with PAS (Figure 5.1B, arrow 4). Protein spots were observed to be 
migrating at Mr between 40 to 50 kDa with closely associated pI (estimated between 
pH 3 and pH 4). In chapter 3, we separated the 40-50 kDa glycoprotein on 1-D PAGE 
according to its molecular weight without the additional separation according to pI as 



























   
 
Figure 5.1 2-D PAGE expression profiles of the 40-50 kDa glycoprotein. Purified gastric mucin was 
used to rehydrate 7 cm, pH 3-10 IPG strips. Total volume of the rehydrate (sample with buffer) was 
125 µl. IEF was applied to separate the proteins according to their isoelectric point (pI). The IEF gel 
was applied to an SDS PAGE (12%, w/v) which allowed the resolution of protein spots present at Mr 
40 to 50 kDa. (A) Gel stained with Coomassie Brilliant Blue (100 µg mucin) showing three protein 
spots (arrows 1, 2 and 3). (B) Gels stained with PAS (200 µg mucin) showing only one spot (arrow 4). 
Gels C and D represent gels A and B after cutting. The protein spots were excised manually from the 

























KDa Mw    3                     pH                              10 Mw    3                     pH                              10 















5.2.2 Identification of the 40-50 kDa glycoprotein by MALDI-TOF MS 
 
The gel spots excised from the 2-D PAGE (Figure 5.1, C and D) were prepared and 
digested (see Materials and Methods chapter 2) until a good spectrum defined by 
good peaks was detected. Spots corresponding to the 40-50 kDa glycoprotein were 
analyzed individually by MALDI-TOF MS and the resulting spectra and the 
corresponding histogram of the Mascot probability based score are shown in Figure 
5.2 to 5.5. The protein sequence database (MASCOT) was searched for all proteins 
that matched the submitted masses of peptides generated from the trypsin digested 40-
50 kDa glycoprotein. Peptides that matched the 40-50 kDa glycoprotein are inserted 
(red) in all spectra. The three Coomassie Brilliant Blue staining spots excised from the 
2-D gel (Figure 5.1C) were identified as alpha-1-acid glycoprotein (orosomucoid) 
with a Mowse score greater than 64 (Figure 5.2 to 5.4) while the PAS staining spot 
(Figure 5.1D) could not be positively identified, confirmed by a low Mowse score of 
40 (Figure 5.5). As can be seen in the spectra, there are similarities in the peak series 
for spots 1(Figure 5.2) spot 2 (Figure 5.3) and spot 3 (Figure 5.4), different from the 
peak series for spot 4 (Figure 5.5). The most abundant peptide at peak 1743.8309 
(spot 1), 1743.7505 (spot 2) and 1742.8044 (spot 3) was common in all three 
Coomassie Brilliant Blue stained spots. The most abundant peptide for the PAS 
stained spot, at peak 1651.9033, differed from that shown by the Coomassie Brilliant 
Blue stained spots. A summary of the three Coomassie Brilliant Blue spots identified 

























































Figure 5.2 MALDI-TOF mass spectrum and the histogram of the Mascot probability based score 
(the Mowse score) of spot 1. The Coomassie Brilliant Blue spot (spot 1) resolved on 2-D PAGE was 
excised from the gel, digested with trypsin and then analyzed by MALDI-TOF MS for the acquisition 
of the spectrum of the (40-50 kDa glycoprotein) peptides. The Mascot database was searched to detect 
all peptides that matched with the masses of the peptides from the digested spot (spot 1) (obtained 
during the spectrum acquisition). The spot was positively identified as alpha-1-acid glycoprotein with a 
high and significant (p<0.05) Mowse score of 68. Peptides matched from the database are inserted (in 
red) into the right hand corner of the spectrum.   
 
 
        Matched peptides (Red) 
 
     1 MALSWVLTVL SLLPLLEAQI PLCANLVPVP ITNATLDQIT GKWFYIASAF  
    51 RNEEYNKSVQ EIQATFFYFT PNKTEDTIFL REYQTRQDQC IYNTTYLNVQ  
   101 RENGTISRYV GGQEHFAHLL ILRDTKTYML AFDVNDEKNW GLSVYADKPE  
   151 TTKEQLGEFY EALDCLRIPK SDVVYTDWKK DKCEPLEKQH EKERKQEEGE  
   201 S 






















































Figure 5.3 MALDI-TOF mass spectrum and the histogram of the Mascot probability based score 
(the Mowse score) of spot 2. The Coomassie Brilliant Blue spot (spot 2) resolved on 2-D PAGE was 
excised from the gel, digested with trypsin and then analyzed by MALDI-TOF MS for the acquisition 
of the spectrum of the (40-50 kDa glycoprotein) peptides. The Mascot database was searched to detect 
all peptides that matched with the masses of the peptides from the digested spot (spot 2) (obtained 
during the spectrum acquisition). The spot was positively identified as alpha-1-acid glycoprotein with a 
high and significant (p<0.05) Mowse score of 64. Peptides matched from the database are inserted (in 
red) into the right hand corner of the spectrum   
 
 
        Matched peptides (Red) 
 
     1 MALSWVLTVL SLLPLLEAQI PLCANLVPVP ITNATLDQIT GKWFYIASAF  
    51 RNEEYNKSVQ EIQATFFYFT PNKTEDTIFL REYQTRQDQC IYNTTYLNVQ  
   101 RENGTISRYV GGQEHFAHLL ILRDTKTYML AFDVNDEKNW GLSVYADKPE  
   151 TTKEQLGEFY EALDCLRIPK SDVVYTDWKK DKCEPLEKQH EKERKQEEGE  
  201 S
Spot 2 spectrum 




















































Figure 5.4 MALDI-TOF mass spectrum and the histogram of the Mascot probability based score 
(the Mowse score) of spot 3. The Coomassie Brilliant Blue spot (spot 3) resolved on 2-D PAGE was 
excised from the gel, digested with trypsin and then analyzed by MALDI-TOF MS for the acquisition 
of the spectrum of the (40-50 kDa glycoprotein) peptides. The Mascot database was searched to detect 
all peptides that matched with the masses of the peptides from the digested spot (spot 3) (obtained 
during the spectrum acquisition). The spot was positively identified as alpha-1-acid glycoprotein with a 
high and significant (p<0.05) Mowse score of 67. Peptides matched from the database are inserted (in 
red) into the right hand corner of the spectrum   
Matched peptides (Red) 
 
     1 MALSWVLTVL SLLPLLEAQI PLCANLVPVP ITNATLDQIT GKWFYIASAF  
    51 RNEEYNKSVQ EIQATFFYFT PNKTEDTIFL REYQTRQDQC IYNTTYLNVQ  
   101 RENGTISRYV GGQEHFAHLL ILRDTKTYML AFDVNDEKNW GLSVYADKPE  
   151 TTKEQLGEFY EALDCLRIPK SDVVYTDWKK DKCEPLEKQH EKERKQEEGE  
   201 S 























































Figure 5.5 MALDI-TOF mass spectrum and the histogram of the Mascot probability based score 
(the Mowse score) of spot 4. The PAS spot (spot 4) resolved on 2-D PAGE was excised from the gel, 
digested with trypsin and then analyzed by MALDI-TOF MS for the acquisition of the spectrum of the 
(40-50 kDa glycoprotein) peptides. The Mascot database was searched to detect all peptides that 
matched with the masses of the peptides from the digested spot (spot 4) (obtained during the spectrum 
acquisition). The spot could not be positively identified as indicated by a low Mowse score of 40. 





Matched peptides (Red) 
 
     1 MSHHPSGLRA GFSSTSYRRT FGPPPSLSPG AFSYSSSSRF SSSRLLGSAS  
    51 PSSSVRLGSF RSPRAGAGAL LRLPSERLDF SMAEALNQEF LATRSNEKQE  
   101 LQELNDRFAN FIEKVRFLEQ QNAALRGELS QARGQEPARA DQLCQQELRE  
   151 LRRELELLGR ERDRVQVERD GLAEDLAALK QRLEEETRKR EDAEHNLVLF  
   201 RKDVDDATLS RLELERKIES LMDEIEFLKK LHEEELRDLQ VSVESQQVQQ  
   251 VEVEATVKPE LTAALRDIRA QYESIAAKNL QEAEEWYKSK YADLSDAANR  
   301 NHEALRQAKQ EMNESRRQIQ SLTCEVDGLR GTNEALLRQL RELEEQFALE  
   351 AGGYQAGAAR LEEELRQLKE EMARHLREYQ ELLNVKMALD IEIATYRKLL  
   401 EGEESRISVP VHSFASLNIK TTVPEVEPPQ DSHSRKTVLI KTIETRNGEV  









Probability Based Mowse Score for spot 4 











Table 5.1 The Mr 40 to 50 kDa Coomassie Blue spots identified by MALDI-TOF 






















3-4 46.994 40-50 68 alpha-1-acid 
glycoprotein 1 
precursor 
[validated] - human 
2 4.93 3-4 46.994 40-50 64 alpha-1-acid 
glycoprotein 1 
precursor 
[validated] - human 
3 4.93 3-4 46.994 40-50 67 alpha-1-acid 
glycoprotein 1 
precursor 




5.3 Discussion      
 
This study was begun in the 90’s based on a laboratory observation of the presence of 
a 40-50 kDa glycoprotein in mucins purified from patients with gastric cancer which 
was absent in the normal gastric mucosa. In Chapter 3 we described how the antibody 
was raised to this glycoprotein and in Chapter 4 we showed the location and 
expression of this glycoprotein in normal, intestinal metaplasia and carcinoma of the 
stomach. We then attempted to identify this 40-50 kDa glycoprotein using 
proteomics. A detailed analysis of the 40-50 kDa glycoprotein was carried out by 
MALDI-TOF MS. This technique is the most accurate method for the identification of 
an unknown protei  and allowed for an in-depth analysis of the 40-50 kDa 
glycoprotein. The finding that the 40-50 kDa glycoprotein is AGP was not expected, 
although this discovery is supported by our previous findings in that the protein 
composition suggested that this was an N-linked glycoprotein (Mall et al., 1999). 
 
Some experimentation was carried out to determine the optimum conditions for 2-D 
PAGE to avoid horizontal and/or vertical streaking due to overloading and to improve 
focusing of spots into tight spots and not smears. We used 100 µg of mucin sample 
for 2-D PAGE stained with Coomassie Brilliant Blue and 200 µg for the PAS stained 
gels because Coomassie Brilliant Blue is a more sensitive stain than PAS. The 











high quality protein samples and loading the correct amount of protein where the key 
factors ensuring well resolved 2-D gels with a clear separation of the 40-50 kDa spots. 
The 40-50 kDa glycoprotein was well resolved (not overlapping) on the broad range 
IPG strips, (Figure 5.1 A and B, pH 3 to pH 10), thus the use of IPG strips with 
narower pH range (pH 3 to pH 4) was not necessary. IEF was performed on mucin 
purified from cancer and after equilibration with SDS buffer in the presence of DTT 
(used to reduce disulfide bonds for analyzing proteins as single subunits), the IEF gel 
was applied to an SDS gel (12%) which allowed the resolution of three protein spots 
between Mr 40 to 50 kDa.  
 
The proteomics approach provided a more direct assessment of the nature of the 40-
50 kDa glycoprotein. We confirmed the presence or absence of the 40-50 kDa 
glycoprotein in SDS-PAGE (Chapter 3) prior to analysis by 2-D PAGE. Mucin from 
post morten specimens and fresher tissues from transplant donor specimens did not 
contain the 40-50 kDa glycoprotein as confirmed by Mall et al. (1999). Only mucin 
samples containing the 40-50 kDa glycoprotein were analyzed by 2-D PAGE. In 1-D 
PAGE the 40-50 kDa reproducibly stained with PAS (Chapter 3, Figure 3.2A) and 
occasionally with Coomassie Brilliant Blue (Chapter 3, Figure 3.2B) as a single 
component “band” when separated by size. In 2-D PAGE, the 40-50 kDa glycoprotein 
was spread out across, effectively separating into three Coomassie spots (Figure 5.1A) 
and one PAS spot (Figure 5.1B). The four protein spots had a pI range between pH 3 
and pH 4, with the molecular weight ranging between 40 kDa and 50 kDa.  
 
Extensive care was taken when preparing and handling the protein samples to avoid 
contamination (keratin) prior to MALDI-TOF MS identification. Spots 1 to 4 excised 
from the gels were digested with trypsin and the resulting peptide fragments were 
extracted and identified by MALDI-TOF MS. Three protein spots (1 to 3) were 
successfully identified as alpha-1-acid glycoprotein and reconfirmed on numerous 
occasions (Table 5.1), presenting high confidence Mowse scores (p<0.05) (Figure 5.2, 
68 for spot 1; Figure 5.3, 64 for spot 2 and Figure 5.4, 67 for spot 3) which indicate 
identity of extensive homology. Mowse scores >64 are highly significant, leaving 
little room for doubt. The Mowse score uses empirically determined factors to assign 












We were unable in the present study to positively identity the PAS positive spot. The 
MALDI-TOF MS spectra of the PAS spot showed a low Mowse score of 40 (Figure 
5.5), not high enough to get a significant match. Given the Mr size and the pI of the 
PAS spot glycoprotein on 2-D PAGE (Figure 5.1B), it was possible to provide an 
objective measure of the significance of the result presented in Figure 5.5. The PAS 
spot matched Peripherin on the MS database which has a higher molecular weight (Mr 
107.236 kDa) and a higher pI than that observed in the 2-D PAGE (Figure 5.1B) thus 
providing reason to conclude that this result is not significant.  
 
We expected the fourth spot to be identified as the same protein as the other three 
spots stained with Coomassie Blue because of the similarity (in 2-D PAGE) in 
molecular weight and a pI within the range of pH 3 and pH 4. We therefore have 
reasons to believe that several drawbacks of using the PAS stain may have resulted in 
the possible impairment of the peptides thus interfering with the MALDI-TOF MS 
analysis. Countless staining procedures such as SYPRO Ruby and Deep Purple have 
been shown to combine high sensitivity and compatibility with mass spectrometry 
(Nishihara and Champion, 2002). Coomassie brilliant blue staining has been the 
dominating staining method in proteomics because it is highly compatible with mass 
spectrometry analysis and also non-expensive (Nishira and Champion, 2002). In 
contrast, the PAS stain as has not been tested for compatibility with MALDI-TOF and 
we suggest possible chemical modifications might have hindered our ability to 
positively identify the fourth spot. It has been reported that AGP has eight potential 
phosphorylation sites influenced by different physiological conditions (Founier et al., 
2000). Perhaps post-translational modification might be another possibility suggesting 
that the PAS spot is a glycoform of AGP thus different from the three Coomassie 
Blue spots.  
 
A comparison of the MALDI spectra permits the immediate recognition of an overlap 
between several low intensity peaks, 1160.5975 for spot 1; 1160.6007 for spot 2; 
1160.6113 for spot 3 and 1160. 6776 for spot 4, knowledge that leads us to think that 
the PAS positive spot (spot 4) could be related to the three Coomassie spots (spots 1, 
2 and 3). However, we observed a discrepancy for the biggest signal peptides when 
comparing the Coomassie stained spots (1743.8309 for spot 1; 1743;7505 for spot 2; 











the highest intensity in spot 1, 2 and 3 (Figure 5.2 to 5.4) is missing in spot 4 (Figure 
5.5) and this might suggest evidence of chemical modification by PAS, the limitation 
which was expected since certain stains are not compatible with MALDI-TOF MS.  
 
However, a careful analysis of the PAS spot therefore appears to be an absolute 
requirement perhaps with the use of a glycoprotein stain that has been reported to be 
compatible with MALDI-TOF MS. The importance of comparing results obtained 
from the database and results from the gels has clearly shown predictions of MALDI-
TOF to be accurate for the three Coomassie positive spots and to be false for the one 
PAS positive spot. Although 2D-PAGE and MALDI-TOF-MS based proteomics has 
proven powerful for the analysis of the 40-50 kDa glycoprotein, it still remains a 
costly and labor- and time-consuming process. The functional differences of the four 
spots identified by MALDI-TOF MS remains unclear as much as their functional 










































DISCUSSION, CONCLUSIONS AND THE FUTURE 
 
Since 1975, the International Agency for Research on Cancer, in its estimate of the 
global burden of cancer (Parkin et al., 1984) listed gastric cancer as a cancer of high 
fatality, with an estimated 934,000 new cases per year in 2002 (8.6% of the total of 
new cancer cases). Gastric cancer is ranked as the second most common cause of 
death from cancer, with 700,000 reported deaths annually (Parkin et al., 2001, 2002, 
2005) and once ranked as the fourth highest in the world at 69.9/100,000 (Bradshaw 
and Harrington, 1975). 
 
Although it has been suggested that gastric cancer is rare in Africa (Holcombe, 1992), 
the incidence in Central Africa has been reported to be higher than previously 
suggested (Parkin et al., 2003). In South Africa, gastric cancer is prevalent in the 
Western Cape region (Botha, 1972; Bradshaw and Harrington, 1975; Wyndham, 
1985; Sitas and Isaacson, 1992) and is reported to be a fatal malignancy among so-
called Cape Coloured (a hybrid race of Western European, Southern African and 
Asian origin) males (Botha, 1972). 
 
Survival from stomach cancer is moderately good in Japan (52%), where mass 
screening by photofluoroscopy has been practiced since the 1960s. Survival is also 
relatively high in North America, possibly due to early diagnosis through rigorous 
endoscopic screening programmes for gastric disorders. Survival from gastric cancer 
is estimated to be 27% in Western Europe while it is as low as 6% in sub-Saharan 
Africa. There is a strong environmental component to the risk differences for gastric 
cancer. Factors such as H. pylori infection (Morgner et al., 2000) and dietary factors, 
including high intakes of preserved salted foods and nitrates and deficiencies of 
vitamin C and E, certainly play an important role in increasing the risk of gastric 
cancer (Kelley and Duggan, 2003). There is a need for a biochemical marker for pre-
malignant disease and early gastric cancer. The available markers such as carcino-
embryonic antigen (CEA) increase in levels when the disease has spread considerably, 
and are therefore not useful for early detection (Fuchs and Mayer, 1995).  Mucins 











pancreatic cancer and MUC1 for breast cancer (Karanikas et al., 1997). The inability 
to diagnose gastric cancer at an early, localized, and curable stage contributes to poor 
prognosis. Thus, gastric cancer remains a dismal disease and early diagnostic markers 
and therapeutic targets are urgently needed. Previous studies in this laboratory showed 
the 40-50 kDa glycoprotein to be present in crude mucus scrapings of both cancer 
patients and those with ulceration of the mucosa (Mall et al., 1990, 1992, 1999). Thus 
the underlying aim of the isolation and identification of the 40-50 kDa glycoprotein 
reported in this study, has as a future goal, an investigation to determine its potential 
as a marker for pre-malignant and very early malignant disease (Mall et al., 1992). 
Our plan is to assay blood levels of AGP in patients diagnosed with carcinoma of the 
stomach and compare these to blood levels in patients with gastric ulceration, the 
siblings of patients with gastric cancer and those who are normal, with no gastric 
disease whatsoever. 
 
The 40-50 kDa glycoprotein was first described in 1990 by Mall et al. (1990), and 
was found to be associated with albumin, an intriguing find since the mucins were 
purified extensively prior to analysis by SDS-PAGE. It was also present in the gastric 
juice of a patient with gastric cancer (Hakkinen et al., 1991; Mall et al., 2000). The 
unusual nature of the 40-50 kDa glycoprotein prompted us to identify it. We identified 
the 40-50 kDa glycoprotein as alpha-1-acid glycoprotein (AGP), also known as 
orosomucoid, a product of three adjacent genes (AGP-A, AGP-B and AGP-B´) 
(Dente et al., 1987). AGP is predominantly synthesized by hepatic cells and was first 
described in 1950 (Fournier et al., 2000) as a 40-43 kDa glycoprotein (Fournier et al., 
2000) and a 50-60 kDa glycoprotein (Ceciliani and Pocacqua, 2007). Mall et al. 
(1990, 1992) reported the size of the 40-50 kDa glycoprotein to be 50-60 kDa on 4-
20% gradient gels and later 55-65 kDa on 10% gels (Mall et al., 1999), different from 
what was shown here on 12% SDS-PAGE gels (40-50 kDa). Thus, the identification 
(by proteomics) of the 40-50 kDa glycoprotein as AGP would now allow us to 
determine its levels in blood. 
 
The identification of the 40-50 kDa glycoprotein as AGP confirms earlier suggestions 
by Mall et al. (1999) that the fragment was likely to be N-linked as opposed to an O-
linked glycoprotein. The carbohydrate content of AGP represents >45% of the 











sialylated complex-type-N-linked glycans (Ceciliani and Pocacqua, 2007). The five 
N-glycosylation sites of human AGP are not conserved; each of the N-glycosylation 
sites can express any of the glycans. The common terminating carbohydrate is sialic 
acid, constituting 10-12% of the whole sugars. This unusual high content of sialic acid 
is responsible for the low pI (pH 2.8 to pH 3.8) of AGP. A clear decrease in size of 
the 40-50 kDa glycoprotein was seen after treatment with neuraminidase (Mall et al., 
1999), suggesting the presence of sialic acid on the carbohydrate composition of this 
glycoprotein.  Using 2-D PAGE, we found the 40-50 kDa to have a low pI (pH 3 to 
pH 4), comparable to that reported for AGP.  
 
Reduction of purified mucin obtained from gastric cancer samples in DTT and 2M 2-
mercaptoethanol did not dissociate the 40-50 kDa glycoprotein suggesting it to be a 
single entity and not a polymeric structure of subunits joined by disulphide bridges 
(Mall et al., 1990). This glycoprotein also failed to dissociate with boiling in 1% SDS, 
4M guanidinium chloride and 3.5M CsCl (Mall et al., 1990). Indeed, AGP is reported 
to be a single polypeptide chain of 183 amino acids in humans and 187 amino acids in 
rats (Nakano et al., 2004). 
 
AGP has been classified as a positive acute-phase protein (Hochepied et al., 2003) as 
well as a member of the immunocalins (Ceciliani and Pocacqua, 2007; Fournier et al., 
2000). The biological function of AGP remains unkown; however, a number of 
activities of possible physiological significance, such as being a natural anti-
inflammatory and immunomodulatory agent with respect to its anti-neutrophil, anti-
complement activity (Williams et al., 1997) and the ability to down regulate various 
phagocytic functions and T-cell-mediated activities (Hochepied et al., 2003) have 
been described. The immunomodulatory as well as binding activities of AGP have 
been shown to be dependent mostly on its carbohydrate composition (Schmid, et al., 
1973). 
 
The 40-50 kDa glycoprotein was not present in normal crude mucus scrapings (Mall 
et al., 1999) whereas in this study we showed it to be expressed in parietal cells of 
normal human gastric tissue. Why then it is not secreted into the crude mucus of 
normal stomachs (transplant donors and cadavers) (Mall et al., 1992, 1999) is not 











human gastric tissue, extra-hepatic expression of AGP has been reported in several 
other tissues (Sorensson et al., 1999; Fournier et al., 2000). The presence of the 40-50 
kDa glycoprotein in parietal cells reinforces the view that parietal cells produce a 
range of ligands that regulate gastric differentiation. Intrinsic factor is a glycoprotein 
secreted by parietal cells (humans) and it has an important role in the gastrointestinal 
absorption of vitamin B12 (Latner and Merrills, 1957). Failure to produce or utilize 
intrinsic factor results in pernicious anemia. High serum vitamin B12 concentration is 
seen in patients with chronic myelocytic leukemia (CML) (Pitney et al., 1954; Beard 
et al., 1954; Miller and Sullivan, 1958) and this is associated with plasma binding to 
AGP (Weinstein et al., 1959). We are unable to explain the consistent expression of 
the 40-50 kDa glycoprotein in parietal cells of the normal gastric mucosa. It is 
possible that the intrinsic factor found in parietal cells might have binding sites to the 
40-50 kDa glycoprotein. The fact that Weinstein et al. (1959) described the binding of 
vitamin B12 to AGP in sera (which is characteristically bound by the intrinsic factor in 
parietal cells) lends further support to our hypothesis. 
  
We showed that the 40-50 kDa glycoprotein was consistently expressed in the 
columnar cells in both complete and incomplete metaplasia and not in the goblet cells. 
Molmenti et al. (1993) raised the possibility that columnar cells are involved in a 
local response to injury or inflammation by producing acute phase proteins under the 
control of cytokines (IL-1, IL-6, IFN and TNF). Geiger et al. (1988) reported that IL-
6 in vivo, induced gene expression of AGP in rat intestinal epithelial cell lines while 
in this study we showed the expression of the 40-50 kDa glycoprotein in human small 
intestine. 
 
Gendler et al. (1982) presented evidence for the active synthesis of AGP by human 
breast epithelial cells while Sorensson et al. (1999) reported expression of AGP by 
endothelial cells, required to maintain capillary permeability (Haraldsson et al., 1987).  
Twining and Brecher. (1977) found AGP in malignant lung tissue, while Fournier et 
al. (2000) and Crestani et al. (1998) reported AGP gene expression in human and rat 
lung tissue during inflammation. Several studies have reported an association of AGP 
with several neoplastic disorders, including breast and lung cancer, and 
immunologically mediated diseases, such as sarcoidosis (Duche et al., 2000). We 











diffuse, mixed, signet-ring cell and mucinous gastric carcinomas. The stomach, like 
the liver, is involved in a local response to a local injury (intestinal metaplasia and 
gastric tumour) by producing AGP under the control of inflammatory mediators. Our 
results are in agreement with others who have demonstrated extra-hepatic expression 
of AGP. Indeed there is a growing body of evidence that the acute phase response 
may take place in extra-hepatic cells, notably the epithelial cells. To our knowledge, 
this is the first time AGP (40-50 kDa glycoprotein) has shown to be associated with 
mucus and mucins in gastric cancer. Ganz et al. (1984) reported AGP to be highly 
sensitive and specific in the detection of lung cancer. 
 
Interestingly, both this study and the previous studies of Mall et al. (1999, 1992, 
1990), showed the 40-50 kDa glycoprotein to be closely associated with albumin. 
This was shown even after extensive purification of the mucin in a CsCl/GuHCl 
density gradient. We are unable to explain this but are aware that albumin 
concentrations in the stomachs of patients with carcinoma are increased due to 
mucosal bleeding (Rossi et al., 2003; Fletcher et al., 2002). We suspect that the type 
of association between albumin and our glycoprotein of interest is non-covalent. We 
were successful once, in partially separating albumin from the 40-50 kDa 
glycoprotein in sodium dodecyl sulphate at 100°C for one to two minutes, followed 
by gel filtration (Mall et al., 1992). However this was rather costly and laborious and 
was not pursued by us. It is possible that conformational changes either in the 
stomach of these patients or through the denaturing conditions in which the extraction 
of mucins occurs, results in this association between albumin and the 40-50 kDa 
glycoprotein, which is resistant to separation of mucin from the 40-50 kDa 
glycoprotein even in CsCl/4MGuHCl. 
 
Our proteomic findings thus far have conclusively shown the 40-50 kDa glycoprotein 
to be alpha-1-acid glycoprotein which is distinguishable from both mucin and 
albumin. In our previous study, we used the anti-human albumin antibody to reveal 
that the 40-50 kDa glycoprotein was not albumin, but rather that it was associated 
with it. We went to great lengths to show that that this newly identified AGP was not 
an artefact of albumin. We used Coomassie Brilliant blue and Ponceau S stain to 
distinguish albumin from the 40-50 kDa glycoprotein. Mall et al. (1999) reported the 











with mucin and associated with albumin, which persisted in being present even after 2 
CsCl gradient purification steps (Mall et al., 1992). AGP, together with albumin, are 
the most important binding proteins in plasma. Plasma AGP concentration is much 
lower than albumin, but during the acute phase the concentration of AGP is increased 
whereas the concentration of albumin, which is a negative acute phase protein, is 
decreased. Perhaps, this association between AGP and albumin, is similar to what 
would normally occur in the gastric mucosa (extra-hepatic expression) during an 
acute phase reaction. We showed albumin to be expressed in chief cells of the normal 
gastric mucosa while the 40-50 kDa glycoprotein now identified as AGP was 
expressed in parietal cells.  
 
AGP found in the crude mucus fractionates with mucin in a caesium chloride density 
gradient due to its carbohydrate moiety that is greater than 40%. Cranmer et al. (1999) 
suggested in a von Willebrand factor molecule study that the tandem repeat units 
found in mucins originated to catch moving molecules or objects. Mucins have been 
shown to bind bacteria through specific attachment sites (Kubiet et al., 2000). AGP 
has been shown to bind toxic molecules produced by bacteria, thus serving as a 
general protective agent (Moore et al., 1997; Libert et al., 1994). Perhaps AGP might 
be bound to material of similar density, such as mucin, via N-linked glycans. The 
large variations observed in the binding of AGP during physiological and pathological 
states are correlated to the variation in the carbohydrate moiety.  
 
For years the presence of the 40-50 kDa glycoprotein in gastric mucus specimens has 
stimulated interest and the physiological importance of this glycoprotein is currently 
not understood. Since AGP was first identified, there has been a major effort to 
elucidate the occurrence and function of this molecule. Yet, we still have limited 
knowledge on the function of this glycoprotein in vivo. Based on our results, AGP is 
of great interest as a potential marker for the detection of gastric cancer. 
 
Future investigations are recommended to compare the detectability and specificity of 
AGP in the sera of normal and cancer patients using the antibody we developed 
against it. Another project would be to address and circumvent the problems 
encountered with the identification of the PAS positive spot. The high variability of 











prove to be very useful in investigating whether the PAS spot may show differences 
in the AGP glycoforms produced. The functional importance of AGP and mucin in 
the pathology of gastric cancer bears further investigation and therefore justifies the 
request for funding for future projects. 
 
Finally, we need to expand this study with more samples that will enable us to verify 
statistically our findings and give us greater insight into the role of the 40-50 kDa 
glycoprotein in the pathogenesis of gastric disease. Unfortunately we were restricted 
by the scheduling of surgery in our attempts to secure samples for analysis during the 
three year period of this study. The other setback in the collection of samples was that 
a considerable number of patients were deemed by the surgeons to be inoperable 
because of the advanced nature of their disease. However, collection of samples is 
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